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ABSTRACT 
TOBACCO-INDUCED CHANGES TO PORPHYROMONAS GINGIVALIS GENE 
EXPRESSION, PHENOTYPE AND HOST-PATHOGEN INTERACTIONS. 
By 
Juhi Bagaitkar 
15th December, 2010 
Tobacco smoke is a strong and independent risk factor for several chronic 
systemic diseases and also increases susceptibility to a multitude of bacterial infections, 
including periodontal infections. Periodontitis is a chronic inflammatory disease of the 
supporting tissues of the periodontium caused by its chief etiological agent, 
Porphyromonas gingivalis. Smokers are more prone to persistant infections by P. 
gingivalis, and harbor higher numbers of P. gingivalis than non-smokers. However, 
smokers show reduced clinical signs of inflammation compared to non-smokers, making 
diagnosis of periodontal disease in smokers problematic. While several studies delineate 
the different mechanisms of how tobacco smoke alters host response to periodontitis, 
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very little is know about its effects on the virulence profile of P. gingivalis. We 
hypothesize, that tobacco smoke presents an environmental stress to which P. gingivalis 
adapts by altering its gene expression, which in turn will influence its interaction with the 
host. 
Indeed, P. gingivalis micro array and qRT-PCR data show that about 7% of P. 
gingivalis genes are differentially regulated on exposure to cigarette smoke extract (CSE) 
including major and minor fimbrial antigens (FimA and Mfal, respectively) and capsule. 
CSE- induced phenotypic alterations are consistent with increased biofim formation and 
reduced pro-inflammatory potential of intact P. gingivalis. Furthermore chronic exposure 
to P. gingivalis FimA leads to the abrogation of the pro-inflammatory response in a 
TLR2- and IRAKl dependent manner. 
These studies provide some of the first information to explain, mechanistically, 
how tobacco smoke changes the P. gingivalis phenotype in a manner likely to promote P. 
gingivalis colonization and infection while simultaneously reducing the host response to 
this major mucosal pathogen. 
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CHAPTER ONE: INTRODUCTION 
Tobacco smoking is the single and most common preventable cause of premature 
mortality in the United States (1, 2). Tobacco users account for one third of the global 
adult population and it is estimated that tobacco-related health complications will result 
in premature death in 50% of this group (3). About 5-6 million people are killed annually 
by tobacco use and most of these deaths (70%) occur in middle- to low- income countries 
(4). 
Tobacco smokers are at an increased risk for various types of cancers, stroke, 
vascular dysfunction, oral diseases, allergies and multiple chronic inflammatory and 
degenerative disorders (5). Cigarette smoke toxicity is attributed to the presence of more 
than 4000 chemicals, including multiple allergens, irritants, toxins, mutagens and 
carcinogens in the particulate/tar and gaseous phases of tobacco smoke (6). Polycyclic 
aromatic hydrocarbons, benzopyrenes, hydrozxyquinone, acrolein, formaldehyde, 
nitrogen oxides, acetone, ammonia, nicotine, heavy metals like lead and cadmium, free 
radicals etc, all contribute to the disease burden through multiple adverse effects on the 
innate and adaptive immune systems (7) . 
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Active smoking is more hazardous than second hand smoke. Inhaled tobacco is 
associated with more diverse types of diseases than oral tobacco use. However, even 
second hand exposure is indicated in increased susceptibility to, and severity of, multiple 
diseases (8). Exposure to cigarette side stream smoke, a major environmental pollutant, 
for example, significantly increases risk for cardiovascular disease (9), adverse pregnancy 
outcomes (10, 11), infertility (12, 13), genetic aberrations (14) and persistent infections 
(15). Thus tobacco smoke contributes significantly to the global disease burden. 
However, there has been surprisingly little research focusing on how tobacco causes 
diseases, particularly chronic inflammatory and infectious diseases. Therefore, the 
specific underlying mechanisms are still largely unknown. 
Chronic Inflammatory Diseases and Smoking 
Tobacco smoking substantially increases the risk for chronic, inflammatory 
diseases (16-19). This is particularly true for atherosclerosis, acute myocardial infarction, 
stroke and peripheral vascular disease (20, 21), inflammatory bowel disease, chronic 
kidney disease (5, 19), and periodontal diseases (22). Smokers are also pre-disposed to 
autoimmune inflammatory disorders such as systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA) and multiple sclerosis (MS). Again, it is important to point out 
that despite convincing epidemiological associations between tobacco use and such 
diseases, mechanistic insight is poor. For example, in RA, polycyclic aromatic 
hydrocarbons from cigarette smoke are known to induce a pro inflammatory cytokine 
response from fibroblast-like synoviocytes (23). Moreover, there is a strong association 
between tobacco use and joint destruction in RA patients who smoke (24, 25). In SLE 
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patients, the mutagenic nature of tobacco smoke is partly responsible for accumulation of 
DNA abnormalities, particularly double strand breaks and DNA-adduct formation, 
contributing to anti-DNA antibody production. In MS patients, nicotine interferes with 
axonal conduction, exacerbating disease (26). However, deeper mechanistic 
understanding is lacking. 
Smoking induces alterations in several systemic inflammatory markers associated 
with chronic inflammation. Elevated levels of serum fibrinogen, C-reactive proteins 
(CRP), pro-inflammatory cytokines, aberrant expression of inflammatory markers and 
adhesion molecules are common in smokers with increased numbers and chemotaxis of 
neutrophils, monocytes and macrophages in the periphery (26). Such systemic changes 
could account for overt susceptibility to chronic inflammatory diseases in smokers. 
The endothelial dysfunction associated with vascular diseases is induced by many 
tobacco smoke components, such as nicotine, carbon monoxide, nitric oxide and free 
radicals. Indeed, tobacco-induced increases in vascular permeability, adhesion molecule 
expression, leukocyte adherence, and platelet aggregation all contribute towards vascular 
disease progression and atherosclerotic lesion formation (21, 27, 28). Even passive 
smoking increases cardiovascular disease risk by about 30% (29). 
Cigarette smoking is also directly responsible for the majority of chronic 
inflammatory diseases of the airways, such as bronchitis, chronic obstructive pulmonary 
disease (COPD), and emphysema. Smoking is the main etiological factor associated with 
COPD, a progressive disease characterized by airway limitation (30). Increased pro-
inflammatory cytokine expression by airway epithelial cells, immune cell sequestration, 
reactive oxygen species (ROS) generation and matrix metalloprotease (MMP) release, all 
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contribute to perpetuation of inflammation that results in destruction of bronchial tissue, 
chronic lung injury and emphysema (as reviewed by MacNee et al (31)). Besides 
destructive lung diseases, both active and passive smoking has been associated with 
compromised renal function, nephropathies, and glomerular dysfunction (32) leading to 
chronic kidney disease (5, 19). Smoking also increases risk for inflammatory bowel 
disease, and several oral diseases particularly gingivitis and periodontitis (22). 
Infectious Diseases and Smoking 
Tobacco smoke adversely affects the Immune response to pathogenic insults, 
making smokers more susceptible to a multitude of infectious diseases compared to non-
smokers (15). These include respiratory tract infections by several bacterial pathogens, 
including Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus injluenzae 
and Legionella pneumophila (33-37). Tuberculosis is also common in smokers and is 
often exacerbated in a dose-dependent manner (38, 39) with quicker rates of disease 
progression, relapse and higher mortality in smokers compared to non-smokers (40). 
Smoking is also significantly associated with the development of bronchitis and bacterial 
pneumonia (41). 
Besides respiratory illnesses, smokers show higher prevalence of meningitis (42), 
post-surgical or nosocomial bacterial infections (43) and sexually-transmitted bacterial 
infections, such as chlamydia and gonorrhoea (44). Smokers also have an increased 
predisposition to bacterial-induced periodontal diseases (45, 46). Shifts in periodontal 
plaque composition from one primarily constituted by Gram positive, aerobic 
commensals to a more anaerobic, Gram negative microflora that includes overt and 
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opportunistic pathogens is also common in smokers (47). A summary of bacterial 
infections associated with tobacco smoking is listed in Table 1. 
Table 1: Bacterial infections associated with tobacco smoking. 
Infection Odds Ratio (95% CI) 
t « 
Additional.., 
Nasopharyngeal and respiratory 2.5, (1.1-6.0) (36) (33-35,37, 
pathogens (such as S. pneumonia, N. 48-51) 
meningitidis, H. injluenzae, L. 
pneumophila) 
Group A streptococcus sore throat 
L ' 
Legionnaires disease 3.6 (2.1-5.8) (37) (37,53) 
CYstic fibrosis 
smoke exposure (54;' 55) 
Pneumonia 2.6 (1.9-3.5)(58, 59) (34,41,60) 
,.Tuberculosl 1.8 Light (38) (39,40,61, 
3.2 Moderate (38) 
3.7 Heavy (38) 
2.5 (1.2 to 5.1) 
Secondhand (34) 
5 
Bacterial vaginosis 2.7 (69) 
Helicobacter pylori 
k,,' , 
1.9 (1.4-2.5 (72) 
Periodontitis 3.3 (2.3-4.5) Light (77) (78-89) 
7.3 (5.1-10.3) Heavy (77) 
Crohn's disease 3.6 (2.5 - 5.0) Active (94) (91,96,97) 
2.0 (1.3 - 3.3) Secondhand 
(95) 
OtitismeOia 4.12,1.5-11.9 Secondhand (3~, 98-
100) 
Surgical infections 1.2 (1.1, 1.3) (101) (43,102, 
103) 
* The specific OR (95% CI) presented is selected from a single reference. The 
"Additional references" column provides more complete information. 
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Periodontal diseases 
Tobacco smokers are more susceptible than non-smokers to plaque-
induced gingivitis and periodontitis. Periodontitis is a chronic inflammatory, 
infectious disease with a majority of the cases found in developing nations (104, 105). It 
is also highly prevalent in the US affecting, more than 100 million people (106) . 
Inflammatory periodontal diseases represent a risk factor for several chronic and serious 
systemic conditions, such as vascular diseases including stroke (107-110), pulmonary 
disease (111-113), nephritis (114) and pre-term birth (115, 116). 
Gingivitis is reversible and is characterized by redness, swelling, and bleeding 
(117). It can proceed into the more severe, chronic inflammatory periodontitis 
characterized by inflammatory destruction of the supporting soft tissues surrounding the 
teeth, loss of periodontal ligaments, and resorption of the alveolar bone that can lead to 
tooth loss and even edentulism (105, lIS). Increased subgingival infection by several 
Gram negative species such as Aggregatibaeter aetinomyeetemeomitans, Prevotella 
intermedia, Campylobaeter rectus, and the red complex bacteria (Tannerella 
forsynthia, Treponema dentieola and Porphyromonas gingivalis) inhabiting the 
largely anaerobic niche between the tooth surface and the junctional epithelium of the 
periodontium is a hallmark of inflammatory periodontal disease (119). 
Subgingival colonization by pathogens is aided by several immune subverting 
virulence factors expressed by these periodontal pathogens. Bacterial persistence and 
the inflammatory response to such pathogens combine to promote inflammatory tissue 
destruction in periodontitis. Multiple pro-inflammatory cytokines (i.e. IL-l f3, IL-6, 
TNFa, IL-S, and RANKL) lead to osteoclast activation and, subsequently, alveolar bone 
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loss (120). The degree and extent of the inflammatory response to these pathogens is 
determined by several host-specific factors like age, race, genetic polymorphisms, 
underlying immune abnormalities, etc (121). However tobacco smoke is the most 
important environmental risk factor associated with chronic, inflammatory periodontal 
disease (45, 46, 122). 
Figure 1: Immune response to oral biofilm bacteria: T - T cells, B- B celis, M-
Monocytes/Macrophages, P- platelets and '(()J -neutrophils. (Source Adapted from a 
figure appearing on the website of Dr. Loesche, University of Michigan) 
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Smoking and Periodontitis 
Smoking is the single most important risk factor for periodontitis (22). There 
is a dose dependent relationship between smoking status and deteriorating periodontal 
health (123). Smokers are highly susceptible to periodontitis and the disease is often more 
severe compared to non-smokers with increased alveolar bone loss (124), attachment 
loss, percentage of sites with significant attachment loss (125), tooth mobility, and tooth 
loss (126). Patients who smoke are also much more likely to be refractory to treatment 
than non-smokers (88). 
Although cigarette smoking causes both systemic and local changes, components 
of cigarette smoke are found at their highest concentrations intraorally and particularly in 
the gingival crevicular fluid - the serum-derived exudate that enters the mouth via the 
gingival crevice. Several studies report nicotine, and its primary metabolite cotinine, 
both adversely affect proliferation, attachment and chemotactic responsiveness in human 
periodontal ligament fibroblasts (127, 128). Nicotine induced stress response in these 
cells is characterized by elevated levels of c-fos expression (129). Arecoline, another 
toxic component in cigarette smoke, significantly inhibits cell proliferation in a dose-
dependent manner and depletes intracellular thiol levels. Thiols are protective against 
oxidative damage and their depletion may increase susceptibility to oxidative damage by 
oxidants present in cigarette smoke (130). In human gingival fibroblasts, nicotine and 
cigarette smoke condensate both promote membrane-associated MMPs-dependent 
collagen degradation, which may promote attachment loss (131, 132). Chronic 
angiogenic suppression and reduced oxygen tensions (133) also contributes to tobacco-
induced predisposition to periodontal disease. However, very little is known about how 
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tobacco smoke affects periodontal pathogens and, particularly, host-pathogen 
interactions. 
Despite some conflicting data that smoking may not influence the sub-gingival 
micoflora (134-137), the balance of recent data strongly suggests that tobacco-induced 
susceptibility to periodontitis is associated with shifts in the microbial composition of 
complex periodontal plaque communities (72, 138-145). For example, Zambon et al 
showed a higher prevalence of Aggregatibacter actinomycetemcomitans, Tanmirella 
forsythia and Porphyromonas gingivalis in smokers (138). Umeda et al (142) reported an 
increased risk for harbouring Treponema denticola in smokers. Haffajee and Socransky 
(146) showed an increased prevalence of eight species, including P. gingivalis, in current 
smokers, while Eggert et al (141) have shown a higher prevalence and proportion of T 
forsythia, Campylobacter rectus, P. gingivalis and Peptostreptococcus micros in plaque 
samples from smokers. P. gingivalis is found in significantly higher numbers in smokers 
compared to non-smokers and the infection is more persistent (88, 147). The evidence for 
tobacco smoke increasing susceptibility to P. gingiva lis infection and in increasing the P. 
gingivalis infectious load is particularly strong. 
Thus tobacco smoke alters the oral biofilm bacterial composition while 
simultaneously dysregulating host immune response. A summary of cigarette smoke 
induced alterations in the context of periodontal disease are shown in Figure 2. 
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Biofilm 
• filcreased virulence factor 
expression 
• e.g. proteases 
• e.g. rmlbriae 
• e.g. Rag antigens 
• Altered LPS structure 
~ 
Effects 
• Decreased inflammatory potential 
• mcreased virulence 
CSE 
Host Response 
• filcreased MMP secretion 
• mcreased osteoclast activation 
• Decreased phagocytic killing 
• Decreased IgG production 
• Decreased cytokine production 
~ 
Effects 
• Decreased inflammatory potential 
• mcreased destructive capacity 
• Increased infection with pathogens 
• Increased tissue destruction 
• Decreased inflammation 
Figure 2: Summary of effects of cigarette smoke and cigarette smoke extract 
(CSE) on periodontal bacteria, host cells and tissues. 
Porphyromonas gingivalis 
Porphyromonas gingiva lis is a Gram-negative, proteolytic, asaccharolytic 
anaerobe associated with chronic periodontitis III humans (148, 149). It is an 
opportunistic pathogen and colonizes the gingival cavity via several key virulence factors 
such as gingipains, fimbriae, lipopolysaccharide (LPS), capsule, hemagglutinins and 
other outer membrane proteins which aid in attachment and invasion, degradation of 
extracellular matrix proteins, and circumvention of a normally strong pro-inflammatory 
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response to infection (150, 151). The major P. gingivalis virulence factors are discussed 
in the next section. 
Major fimbrial antigen (FimA) 
The major fimbriae of P. gingivalis are long (0.5-1J.lm (152)), hair-like, 
peritrichous, adhesive, filamentous structures that project away from the cell surface and 
are primarily comprised of a 41 kD protein (FimA, fimbrillin) encoded by the FimA gene 
(153). Based on the genomic variations in FimA gene, fimbriae are classified into Types 
I, II, III, IV and V (150). P. gingivalis strains with Type II fimbriae are most commonly 
associated with periodontitis and have been found to be more virulent in mouse models of 
systemic infection compared to TypeIlIV carrying strains (154). Several accessory 
proteins also associate with the major fimbriae such as Fim C, D and E encoded by genes 
downstream of FimA gene in the FimA operon (155, 156). FimCDE deficient strains 
show reduced invasion and persistence in macrophages and induce diminished bone loss 
in mouse models of periodontitis (157). 
P. gingivalis major fimbriae are essential virulence factors in host colonization. 
Fimbriae mediate adhesion to several host proteins such as fibronectin, laminin, collagen, 
and salivary proteins (158); aid attachment to, and invasion of, oral epithelial cells, 
endothelial cells and gingival fibroblasts (159, 160); co-aggregate with other plaque 
bacteria (161); are key in internalization and persistence in macrophages through 
exploitation of complement receptor 3 (CR3) (162); induce pro-inflammatory cytokines 
such as TNF-a, IL-6, but inhibit IL-12 in monocytes and macrophages, thus limiting 
immune clearance (163). They are thought to directly induce alveolar bone loss in murine 
12 
models (164, 165). Several studies have delineated their role in upregulating adhesion 
molecules such as ICAM-I, VCAM-l, P- and E-selectins in endothelial cells (166). 
However, their capacity to induce pro-inflammatory mediators from immune cells is 
controversial. The ability of FimA to generate an inflammatory response might be cell 
type dependent. Contrary to human monocytes, primary human gingival epithelial cells 
stimulated with purified FimA from P. gingivalis 33277 failed to generate a 
pro inflammatory response as indicated by low levels of IL-6 and IL-8 (167). Fimbriae-
deficient strains are also found to be as inflammatory as wildtype strains in mouse scalp 
challenge model indicating FimA is not entirely responsible for the inflammatory 
response associated with P. gingiva lis (168). 
Minor Fimbrial Antigen (Mfa!) 
The minor fimbriae of P. gingivalis are shorter filaments (18-120nm - (169)) 
composed of a 67-kDa protein encoded by the mfal gene (170). Mfal is co-transcribed 
with Mfa2, the product of the mfa2 gene, which is postulated to be important in 
anchoring Mfal in the P. gingivalis membrane and in regulating fimbrial length (171). 
Native minor fimbriae have been shown to contain several putative glycosylation sites 
(172). 
The role of Mfal in P. gingivalis virulence is beginning to be elucidated. Mfal is 
key in co-adhesion to the primary periodontal colonizer, Streptococcus gordonii, through 
specific interaction between Mfal and the SspB protein expressed on the surface of S. 
gordonii (173). Mfa 1 is also important in single species biofilm maturation and 
microcolony development (174). Unlike FimA, Mfal is highly inflammatory and 
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induces IL-6, IL-l~, TNF-a in mouse peritoneal macrophages, endothelial cells (175, 
176) and is associated with alveolar bone loss in various mouse models of periodontitis 
(164, 165). Zeituni et al have shown, using mjal-deficient strains of P. gingivalis, that 
minor fimbriae are important in internalization by monocyte-derived dendritic cells 
through interaction with surface DC-SIGN. Such Mfal-dependent targeting into DC-
SIGN-rich intracellular compartments results in lowered inflammatory cytokine levels 
thus preventing DC maturation and inducing a Th2 biased immune response (177). 
P. gingiva lis LPS 
P. gingivalis is an important virulence factor recognized by the host receptors 
TLR4 and TLR2 (178, 179). It is associated with inflammatory cytokine production in 
human gingival fibroblasts (HGF) (180), macrophages (181), and neutrophils (182, 183), 
as well as direct osteoclast activation and promotion of bone resorption in several in vitro 
and in vivo models (184). It has also been implicated in increasing the risk for other 
systemic conditions in periodontitis patients such as atherosclerosis by inducing foam 
cell formation in murine macrophages (185). 
P. gingivalis LPS is atypical in structure, consisting primarily of tetra- and penta-
acylated Lipid A with one or two phosphate groups. Unlike E. coli LPS (the canonical 
TLR4 agonist), P. gingiva/is LPS displays significant amount of Lipid A structural 
heterogeneity, such as differing numbers of phosphate groups, amounts and positions of 
fatty acids and variations in acyl chain lengths (178). These structural alterations can be 
strain specific and / or altered according to environmental conditions but are directly 
responsible for variations in the immune response to P. gingivalis LPS (186). Both 
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penta- and tetracylated forms of lipidA present are recognized by TLR4, however it is the 
pentaacylated form that is associated with NF-KB activation and E-selectin upregulation 
in endothelial cells (187, 188). Tetraacylated forms can antagonize TLR4 activation and 
may be responsible for modulating and / or subverting the host inflammatory response (as 
reviewed by Hajishengallis (189)). 
P. gingivalis LPS is significantly less inflammatory than E. coli LPS. Various 
mechanisms have been proposed to explain the lower biological activity of P. gingivalis 
LPS, such as decreased affinity for LPS-binding protein (LBP) and subsequent 
recognition by TLR4 (186); increased activation of transcriptionally inactive p50 subunit 
of NF-KB rather than p65 subunit which is associated with transcription of 
pro inflammatory genes in Monocyte derived Dendritic cells (MoDCs) (190); reduced 
activation of lRAKl and increased production of IRAK-M (negative regulator of TLR 
signaling) (191). 
P. gingivalis Capsule 
Some strains of P. gingivalis produce an extracellular capsule composed of 
negatively charged polysaccharide residues. This capsular layer provides resistance 
against phagocytic clearance by neutrophils (192) and complement-mediated lysis or 
opsonization (193). Except for a recent report by Brunner et al (194) stating that the 
presence of capsule reduced inflammatory response to P. gingivalis in human gingival 
fibroblasts, the literature ascribes highly pro-inflammatory potential to P. gingivalis 
capsule, which is associated with increased abscess formation, compared to non-
encapsulated strains, in animal models of systemic infection (195, 196). Dentritic cells 
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challenged in vitro with encapsulated strains of P. gingiva lis (KI-K6 serotypes) produces 
a pro inflammatory response associated with elevated levels ofIL-lr3, IL-6, IL-12p35, IL-
12p40, and IFN-y. The Kl serotype of P. gingivalis W83, used in our microarray 
experiments, was found to be most inflammatory of all P. gingivalis capsule subtypes 
(197). 
Long-term exposure to capsular polysaccharides is associated with a decreased 
ability of periodontal ligament fibroblasts to attach to the tooth root surface (198). P. 
gingivalis serotype K5 capsular polysaccharide mediates co-aggregation between P. 
gingivalis and another periodontal pathogen, Fusobacterium nucleatum (199). 
Furthermore, mice immunized with purified P. gingivalis capsular polysaccharides 
elicited a strong humoral response and were protected from oral bone loss on secondary 
challenge with the whole bacterium (196). The presence of capsular polysaccharides, 
thus, is important in P. gingivalis virulence and likely contributes to the progression of 
periodontitis. 
P. gingivalis Proteases (Gingipains) 
P. gingivalis produces trypsin-like cysteine proteases - the Arg- and Lys-
gingipains encoded by rgpA, rgpB, and kgp genes. Gingipains playa role in multiple 
virulence mechanisms of P. gingivalis. In addition to providing energy through 
degradation, and subsequent metabolism, of extracellular matrix proteins and stimulating 
the expression of matrix metalloproteinases (MMPs), they subvert the host response by 
degrading cytokines, complement proteins and several key immune receptors, including 
macrophage CD 14 and T cell CD4 and CD8 receptors. Moreover they perpetuate 
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inflammation and activate the blood coagulation system, enhancing vascular 
permeability, promoting gingival edema and inducing platelet aggregation (as reviewed 
by (200, 201)). 
Smoking and inflammatory response in Periodontitis 
Chronic exposure to tobacco smoke adversely affects host reponse in 
periodontitis. More than 50% of cases of periodontitis are found in current or ex-smokers. 
Tooth and bone loss in smokers is directly influenced by tobacco consumption in a dose 
dependent manner (202). Contrary to the increased severity of disease, smokers 
consistently show reduced signs of clinical inflammation such as bleeding on probing, 
gingival redness (203) accompanied by reduced levels of pro-inflammatory markers (47, 
133,204). 
Inflammatory dysregulation in smokers can be attributed to the debilitating effects 
of tobacco smoke on both innate and adaptive immune responses. Smoking is associated 
with inappropritate activation of neutrophils (205), neutrophil elastase and matrix 
metalloproteinases release (206-208); inhibition of key endogenous protease inhibitors 
(a I-antitrypsin and a2-macroglobulin) (209) contributing to destruction of gingival 
tissues. Periodontal breakdown in smoking patients has recently been associated with 
increased T-cell proliferation (210). Furthermore, smoking contributes to alveolar bone 
loss (and osteoporotic bone resorption) by promoting the differentiation and activation of 
osteoclasts (211-213) and it may also adversely influence fibroblasts by inhibiting cell 
proliferation and attachment (127, 130). Thus, inflammatory dysregulation is an 
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important contributing factor to the increased severity of periodontitis and is likely to 
influence disease progression in periodontitis. 
Tobacco smoke components are readily available in the gingival crevicular fluid 
and are likely to alter the host pathogen interactions of plaque bacteria. Smoking causes a 
shift in the normal microbial flora, increased prevalence, numbers and persistence of P. 
gingivalis in infected individuals (47). Thus it is likely that the tobacco smoke influences 
P. gingivalis virulence in smokers while maintaing inflammatory response suppression. 
While several studies delineate the different mechanisms of how tobacco smoke alters 
host response to periodontitis very little is known about its effects on the virulence profile 
of P. gingivalis. 
Our main objective in this dissertation was to identify differentially expressed 
proteins and lipids of P. gingivalis regulated by cigarette smoke focusing primarily on 
secreted and cell surface components since these represent likely candidates that can 
influence virulence and interactions with host tissues. Membrane proteins play an 
essential role in colonization, biofilm formation and development of disease as well as 
the immune response to P. gingivalis while gingipain activity is central to many aspects 
of P. gingivalis physiology and contributes to nutrient acquisition, virulence and the 
processing of cell surface components. Thus cigarette smoke induced changes in the key 
pathogenic determinants of P. gingiva lis are likely to alter host pathogen interactions in a 
manner that promotes reduced inflammatory response but increased infection. 
Our main hypothesis is that tobacco smoke presents an environmental stress to 
which P. gingivalis adapts by altering its gene expression and altering phenotypic traits 
that are likely to influence host-pathogen interactions. Our studies would help determine 
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how P. gingivalis responds to cigarette smoke at the molecular level and delineate the 
mechanisms that contribute to the observed suppression of inflammatory response in 
smokers. 
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CHAPTER TWO: MATERIALS AND METHODS 
Reagents and antibodies: 
DMEM, RPMI 1640 and keratinocyte-serum-free (KSF) media, Dulbecco's PBS, 
bovine pituitary extract, Amphotericin Band Nu-Page 4-12% Bis-Tris gels and all other 
SDS-PAGE chemicals were obtained from Invitrogen (Carlsbad, CA). FBS came from 
HyClone (Logan, UT). THP-l, THP-l Blue, TLR-transfected Human Embryonic Kidney 
(HEK) 293 and vector control cells as well as Pam3CSK4, FSL, LPS, normocin, 
blastocidin, zeocin, hygrogold and QUANTI-Blue NF-KB assays were purchased from 
Invivogen (San Diego, CA). Penicillin-streptomycin came from Mediatech (Manassas, 
VA). RIP A buffer, PhosSTOP and complete Mini EDTA-free protease inhibitor cocktail 
tablets were bought from Roche (Indianapolis, IN). BCA Protein Assay kits came from 
Pierce (Rockford, IL). SuperSignal West Pico Chemiluminescent Substrate kits and 
Bacterial Protein Extraction Reagent (B-PER) were purchased from Thermo Scientific 
(Rockford, IL). FimA-specific antibodies were custom generated by Cocalico 
Biologicals, Reamstown, PA, while FITC-Iabeled mouse anti- human CD16b and mouse 
IgM-FITC isotype control antibodies came from AbD Serotec (Oxford, UK). The E38 
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monoclonal anti-RagB antibody was a kind gift of Dr. Mike A. Curtis of The London, 
Queen Mary's School of Medicine and Dentistry, UK. Fibronectin pre-coated microplates 
were from BD Biosciences (San Jose, CA). Anti-P. gingivalis antibodies were generated 
in house, while HRP-linked anti-rabbit IgG and all other antibodies were purchased from 
Cell Signaling Technology (Beverly, MA). Gifu anaerobic medium (GAM) was bought 
from Nissui Pharmaceuticals (Tokyo, Japan). Lymphocyte separation medium (LSM) 
was purchased from MP Biologicals (Solon, OH). Dextran, PBS and 
tetramethylbenzidine were obtained from Fisher Scientific (Fair Lawn, NJ), EDTA from 
AA Hoefer Inc. (San Francisco, CA), while trypan blue, insulin, transferrin, 2-
mercaptoethanol, 2-aminoethanol, sodium selenite, proteinase K acrylic beads and 
phosphotongstic acid were purchased from Sigma-Aldrich (St. Louis, MO). HiTrap 
Chelating HP affinity columns came from Amersham Biosciences Corp., (Piscataway, 
NJ). Isopropyl-p-D-thiogalactopyranoside (IPTG) was bought from RPI Corporation 
(Prospect, IL). Limulus amoebocyte lysates assay kit was purchased from Cape Cod Inc. 
(Falmouth, MA). IL-8 ELISA kits were from Cell Sciences (Canton, MA). TNF-a, IL-6 
and IL-I0 ELISA kits and FITC conjugated anti-human TLR2 and appropriate istoype 
control antibodies were purchased from eBioscience (San Diego, CA). Formavar coated 
copper grids were from Electon Microscopy Sciences (Hatfield, PA). Finally, standard 
reference cigarettes were obtained from the Kentucky Tobacco Research and 
Development Center (Lexington, KY). 
Lysozyme was purchased from Sigma, St. Louis, MO; RNA Midi and PCR 
purification kits from Qiagen, Valencia, CA; random hexamers from Biosynthesis, 
Lewiston, TX; RT buffer, DTT, RT-PCR mastermix and Superscript II from Invitrogen, 
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Carlsbad, CA; 2:3 amino allyl dUTP:dTTP ratio labeling mIX from Amersham 
Biosciences, Piscataway, NJ. P. gingivalis W83 microarrays were obtained from The J. 
Craig Venter Institute through the NIDCR Oral Microbe Microarray Initiative (NOMMI). 
Bacterial culture and in vitro modeling of tobacco exposure: 
Porphyromonas gingivalis W83 and A TCC 33277 were purchased from the 
American Type Culture Collection (Manassas, VA) and maintained as frozen stocks. P. 
gingivalis was grown in GAM or GAM conditioned with CSE (GAM-CSE) under 
anaerobic conditions (80% N2, 10% H2, 10% C02) at 37°C in a Coy Laboratories 
anaerobic chamber. Bacteria were harvested at mid- to late-exponential phase (O.D. of 1 
corresponds to 109 cells mrl). To prepare GAM-CSE, cigarette smoke was drawn 
through 50 ml GAM by using a three-way stopcock and a syringe, with 35ml 'drags' 
performed over a period of 2 sec, one drag every 2 sec. Cigarette smoke extract-
conditioned medium was filtered (0.22 f..l), and adjusted to pH 7.2. The nicotine content of 
GAM-CSE was determined by gas-liquid chromatography, as previously described (214) 
and GAM-CSE adjusted to physiologically relevant doses (214-217). Unless otherwise 
noted, GAM-CSE was employed at a concentration of 4000 ng nicotine equivalents Iml. 
For all experiments P. gingivalis was either cultured in GAM or CSE for two passages. 
CSE grown P. gingivalis was cultured back in GAM for two more passages for the 
reconditioned group. 
Human PBMC, neutrophil and gingival epithelial cell isolation and maintenance: 
Human peripheral blood mononuclear cells (PBMCs) were isolated from de-
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identified whole, citrated (10%) venous blood obtained from healthy donors by 
separation and collection of buffy coat and elimination of erythrocyte contamination with 
Histopaque 1077 density gradients, as previously described (218). Written informed 
consent was obtained from all the donors, and studies performed in compliance with 
University of Louisville, Institutional Review Board, Human Subjects Protection 
Program, (study number 503.05). Viability of all cells was routinely >98%, as 
determined by trypan blue exclusion. PBMCs were maintained in RPMI-1640 
supplemented with 10% heat inactivated FBS, 100u/ml penicillin G and 100/-lg/ml 
streptomycin, at 37°C, 5% C02. Cells were allowed to rest overnight before addition of 
agonists. 
Neutrophils were isolated from the erythrocyte-neutrophil pellet by collection 
from 1 % Dextran- DPBS suspensions and elimination of erythrocyte contamination by 
hypotonic lysis. On restoring isotonicity, cells were washed once with cold DPBS and 
once with plasma buffer (2% plasma in DPBS). Neutrophils were suspended in RPM 1-
1640 supplemented with 10% heat inactivated FBS, 100u/ml penicillin G and 100/-lg/ml 
streptomycin, at 37°C, 5% C02. Viability was routinely >98%, as determined by trypan 
blue exclusion. Purity of neutrophils was routinely >95%, as determined by flow 
cytometry using FITC-Iabeled anti-CD 16b. 
The human gingival epithelial cell line, OBA-9, was obtained from Dr. Denis 
Kinane (University of Pennsylvania, PA) and maintained at 37°C, 5% CO2 in KSF 
medium supplemented with 10 /-lg/ml of insulin, 5 /-lg/ml of transferrin, 10 /-lM 2-
mercaptoethanol, 10 /-lM of 2-aminoethanol, 10 nM of sodium selenite, 50 /-lg/ml of 
bovine pituitary extract, 100 units/ml of penicillin/streptomycin and 50 ng/ml 
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Amphotericin B. 
TNF-a release from P. gingivalis-stimulated PBMCs: 
PBMCs (O.S x 106 cells per well) were stimulated with 106 - 109 P. gingivalis 
grown in GAM or GAM-CSE. Cell-free supernatants were harvested by centrifugation 
and TNF -u cytokine levels were determined by ELISA. 
P. gingivalis W83 microarrays: 
P. gingivalis W83 microarrays were obtained from The J. Craig Venter Institute 
through the NIDCR Oral Microbe Microarray Initiative (NOMMI). To determine how 
exposure to CSE influences the activity of the P. gingivalis genome, we compared gene 
expression in P. gingivalis W83 grown in control (GAM) and conditioned (CSE-GAM) 
media. Microarrays were performed on triplicate GAM and GAM-CSE cultures. Total 
RNA from control and experimental cultures was isolated by extraction from washed 
cells with hot phenol followed by chloroform extraction and isopropanol precipitation. 
RNA was purified and genomic DNA was removed using a Qiagen Midi kit with on-
column DNAse treatment followed by further digestion with RNAse-free DNAse to 
remove any trace contamination of genomic DNA. The synthesis of labeled cDNA was 
carried out by methods established by The J. Craig Venter Institute (www.jcvi.org). 
Briefly, 2-2.Sllg of total RNA was mixed with SOOng of random hexamers, incubated at 
70°C for 10' and transferred to ice. A SO x 2:3 aminoallyl dUTP:dTTP ratio labeling mix 
containing 2S mM remaining nucleotides, S x RT buffer, 3 III of 0.1 M DTT and 2 III 
Superscript II (200U/IlI) were added. Samples were then incubated for 10' at room 
temperature and transferred to 42°C, overnight. Reactions were stopped with 10 III of IN 
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NaOH and 10 III of 0.5 M EDTA for 15' at 65°C and neutralized with 25 III 1M Tris, pH 
7.4. Unincorporated aa-dUTP and free amines were removed using a Qiagen QIAquick 
PCR purification kit protocol with phosphate buffers. The cDNA was then dried down in 
a speed vacuum and resuspended in 4.5 III of 0.1 M sodium carbonate buffer, pH 9.0. 
The appropriate NHS-ester Cy3 or Cy5 dye in DMSO was added (4.5 Ill) and the reaction 
incubated at room temperature in the dark for 2 hours. The reaction was neutralized by 
adding 35111 of 100 mM sodium acetate, pH 5.2. The labeled cDNA was purified to 
remove any uncoupled dye using the Qiagen PCR purification kit with Minelute columns 
and an extra wash. The labeled cDNA was quantified and evaluated by 
spectrophotometry and equivalent pmol of Cy3 and Cy5 samples were combined, dried 
down, and stored at -80°C. Hybridization and subsequent analysis of the arrays was 
carried out following protocols established by The J. Craig Venter Institute, essentially as 
described by (219). Arrays were pre-hybridized at 42°C for 1 hr in 5 x SSC/O.l %SDS/ 
1 % BSA and washed several times with MilliQ water. Washed arrays were then dipped 
into isopropanol and dried by centrifugation at 1000 rpm for 10 minutes. For 
hybridization, Cy3/Cy5 probe mixtures were suspended in 50111 hybridization buffer 
(50% formamide, 5 x SSC, 0.1 %SDS, 0.1 mM DTT, 0.56 Ilg/ml sheared salmon sperm 
DNA), heated then applied to the array under a Lifter™ cover slip. The array was 
incubated at 42°C in a sealed chamber for 15-20 hr. After hybridization, the array was 
washed twice in 2 x SSC/O.l % SDS at 55°C, twice in 0.1 x SSC/O.1 %SDS, once with 0.1 
x SSC, water rinsed, and dried. Arrays were then scanned using an Axon slide reader, 
scanning in the Cy5 channel and the Cy3 channel. Identification and calculation of spots 
was carried out usmg the TIGR Spotfinder software 
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(http://www.jcvi.org/cms/research/softwareD. Subsequent nonnalization of fluorescent 
data was conducted using TIGR-MIDAS (also freely available from TIGR). Subtraction 
of local background and integration of Cy5 and Cy3 fluorescent intensities was calculated 
using Excel. Array experiments were carried out in triplicate using independently isolated 
RNA samples. Genes that are up- or down-regulated by greater than 2-fold in the post-
nonnalized consensus were classified as differentially expressed, as presented and further 
detailed in Figure 3. 
Validation of array data: 
Differentially expressed genes of interest were con finned by quantitative real-
time reverse transcription-PCR using an Applied Biosystems 7500 Real-Time PCR 
system, essentially as described previously (220). Primers were designed using the real-
time PCR primer design software provided by GenScript (www.genscript.com/ssl-
bini app/ primer): 
PG1055 (F: CCTACAGATTGGAGGTGGCT, R: ATAGGCATGGTATGCTGCAA); 
PG2102 (F: ATCGTTTGGTCTGATACGCA, R: CTGCACGTTCAGCCTGTATT); 
PG2100 (F: ATTACAAGATGGCTGTGGCA, R: TGCTGTCATGACTGTCCAAA); 
PG2008 (F: ATTCTTAGGAACGAGCGCAT, R: GGGATTCCCTTGATCGAGTA); 
PG1286 (F: AGCGATCAATGACCAAATCA, R: CACGGCATCGATAGCTTCT); 
PG 1552 (F: GA TTTGAAGCCGGAGAAGAG, R: TAAGGCAGTACCACATTCGC); 
PG0111 (F: AGGCAACGGAGAAGTATCGT, R: AAAGCACCATCAATGACGAA); 
PG1432 (F: ACAGCTCGAACTGCATCAAC, R: CTGCATATAAGTGCGGGCTA); 
PGOl17 (F: TCTCGAACGACCAATAGTGC, R: CATTCTCTGCAATCGGCTTA); 
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PG2132 (F: GTAAATCTGGAGCCAACCGT, R: CGAGTAACGGCAAGAGGAGT); 
and 
PG1548 (F: TGGAAGATGCCTCATGGATA, R: GTAATGCTGAAAGTCGGCAA). 
P. gingivalis W83 outer membrane protein profiling: 
Outer membrane preparations were obtained from P. gingivalis cells grown in 
GAM or GAM-CSE. Briefly, the cell pellet was suspended in 10mM Tris, pH 7.5, 1mM 
EDTA (TE) containing 100 ~g/ml lysozyme and protease inhibitor cocktail and was 
incubated for 15 minutes at 25°C. The cell suspension was sonicated three times on ice 
and cellular debris was removed by centrifugation at 1000 x g for 10 minutes. The 
supernatant was subsequently centrifuged at 100,000 x g for 60 minutes. The membrane 
pellet was suspended in 5 mls TE containing 0.5M NaCI and centrifuged again at 100,000 
x g for 60 minutes. After discarding the supernatant, the membrane pellet was suspended 
in 5 ml MgCh containing 1% Triton X-100. Triton X-100 insoluble material was then 
collected by centrifugation at 100,000 x g. The resulting outer membrane fraction was 
suspended in TE containing 0.5% SDS and analyzed by PAGE. Outer membrane 
preparations (20 ~g protein) were electrophoresed through 4-15% gradient SDS-PAGE 
gels and protein bands were visualized by staining with Coomassie brilliant blue R-250. 
Gel image analysis and densitometry were performed using the Kodak 4000MM Image 
Station system (Eastman Kodak, New Haven, CT). Protein identification was achieved 
by excision of the protein bands of interest (see Figure 8) from SDS-PAGE gels, 
followed by in-gel trypsin digestion, peptide preparation, MALDI-MS analysis, and 
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bioinfonnatic identification by peptide mass fingerprinting using the core facilities at the 
University of Louisville core proteomics laboratory. 
Expression of RagB in response to eSE: 
P. gingiva lis cells were sequentially passaged in GAM, GAM-CSE and or 
reconditioned back in GAM, respectively. Bacterial cells were lysed (10mN Tris, 100mM 
NaCI and lmM EDTA) and probed by western blot (20 J.lg protein per lane). Total 
protein estimated using a BCA protein assay kit. MAbE38, an anti-RagB antibody, was a 
kind gift from Mike A. Curtis. Anti-Rabbit HRP-linked IgG was used as the secondary 
antibody. Probing and visualization of immunoreactive bands was perfonned by 
chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate kit as per 
the manufacturer's protocol. Gel image analysis and densitometry were perfonned using 
the Kodak 4000MM Image Station system. 
Analysis of capsule production and FimA expression on eSE-exposure: 
Mid- to late-log phase P. gingiva!is, grown in GAM or GAM-CSE, were mounted 
on a formvar-coated copper grid, negatively stained with phosphotungstic acid at pH 7.0, 
and the bacteria visualized using a Philips CM-IO Transmission Electron Microscope. 
Total P. gingiva/is lysate (1 x 105 mid-late log cells) for Western blots were obtained 
from cells passaged twice in GAM, twice in GAM-CSE, or twice in GAM-CSE then 
reconditioned in fresh GAM. Western blots were probed with rabbit anti-FimA sera and 
HRP-linked anti-rabbit IgG. Immunoreactive bands were visualized by 
chemiluminescence. Imaging and densitometry were perfonned using the Kodak 
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4000MM Image station. 
Analysis of FimA binding activity and surface availability: 
Adhesion of mid- to late log phase CSE-exposed and control P. gingiva lis cells to 
the extracellular matrix protein and FimA ligand, fibronectin, was measured by ELISA 
using fibronectin coated microplates plates, rabbit anti-Po gingivalis antibody followed by 
HRP-linked anti-rabbit IgG antibody and tetramethylbenzidine as the chromogenic 
substrate, essentially as previously described by Pierce et al (221). Similarly, surface 
accessibility of FimA presented on mid- to late- log phase CSE-exposed and control P. 
gingivalis cells was estimated by ELISA using rabbit anti-FimA antibody. 
Analysis of P. gingivalis biofilm formation: 
Formation of mono-species P. gingivalis biofilms was examined, using a similar 
procedure to that described by Oaep et al for bi-species biofilms (222). Briefly, P. 
gingivalis cultures grown to late log phase either in GAM or GAM-CSE were introduced 
into BST FC 71 flow cells (Biosurface Technologies Corp., Bozeman, MT) with saliva 
coated cover slips at a flow rate of 6 mllhr for 2hr. Flow was maintained using a 
Manostat Carter 4/8 cassette peristaltic pump (Fisher Scientific, Suwanee, GA). Bacteria 
were then fed with either GAM or GAM-CSE for 48hr. Resulting P. gingivalis biofilms 
were visualized by FITC staining. The depth of FITC-Iabeled P. gingiva lis biofilm was 
determined on an Olympus Fluoview confocal laser scanning microscope (Olympus, 
Pittsburgh, PA) from 5 frames randomly chosen by Fluo View (Olympus, Pittsburgh, PA). 
Microcolony depth was determined by performing Z-plane scans from 0 f.lm to 50 f.lm 
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above the cover glass surface. Biofilm characteristics (depth, total surface area covered, 
substratum coverage, average and total thickness) were computed using Matlab v7.5.0 
and Comstat (The Mathworks Inc., Natick, MA) (169). 
Purification of rFimA and rMfal: 
Recombinant FimA and Mfal proteins were induced in Escherichia coli vectors 
containing FimA or Mfal cloned into pET-30 expression system, as previously described 
by Park et al . The C-terminal penta-histidine tagged recombinant proteins were induced 
in Escherichia coli by IPTG and purified using HiTrap chelating HP affinity columns. 
Purity of recombinant proteins was confirmed by SDS-PAGE. The lack of contamination 
by LPS, or other inflammatory mediators, was confirmed by several measures, that is, 
assessment of pro-inflammatory activity (TNF-a production by PBMCs) of recombinant 
proteins digested with proteinase K attached to acrylic beads; assessment of pro-
inflammatory activity (TNF-a production by PBMCs) of recombinant proteins following 
boiling in 2% SDS; and the limulus amebocyte lysate assay. 
Pro-inflammatory profiling of FimA and Mfal: 
0.5 x 106 PBMCs or neutrophils per well were seeded in 96-well plates and 
stimulated with l~g/ml rFimA, rMfal, or TLR-specific agonists (E. coli LPS, 
Pam3CSK4 and FSL). TNF-a, IL-6, and IL-IO (PBMC) and IL-8 (neutrophil) levels were 
determined in 24 hr supernatants by ELISA. OBA-9 cells were seeded at 0.1 x 106 cells 
per well in 12-well plates. On reaching confluence (48 hr) the epithelial cells were 
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stimulated with rFimA, rMfal, LPS, Pam3CSK4 and FSL. 24 hr OBA-9 culture 
supernatants were assayed for IL-8 by ELISA. 
TLR-specificity of FimA and Mfal: 
Human Embryonic Kidney (HEK) 293 cells expressing either TLR2/1, TLR2/6, 
TLR4, TLR4-CDI4-MD2 and HEK TLR null cells were maintained at 37°C in 5% CO2 
in DMEM medium supplemented with 10% FBS, 100Jlg/ml normocin and 1 o Jlg/m I 
blastocidin. 50Jlg/ml hygrogold was added to the additionally to the above media for 
TLR4-CDI4-MD2 cell maintenance. TLR activation in each cell line was measured as 
IL-8 induction 24 hr post-stimulation with rFimA, rMfal or specific TLR positive control 
agonists. 
Induction of TLR2 tolerance by FimA: 
To determine if rFimA induced TLR2-specific tolerance, PBMCs (1 x 106 per 
well) were stimulated, or not, with rFimA (1 Jlg/ml) in 5 ml polypropylene tubes. 24 hr 
culture supernatants were collected, PBMCs washed once with DPBS and re-suspended 
in RPM!. The cells were then restimulated with FimA, Mfal, Pam3CSK4 or E. coli LPS 
(all 1 Jlg/ml) for an additional 24 hrs. TNF-a, IL-6 secretion was measured by ELISA. 
NF-KB induction by FimA and Mfal: 
0.5 x 106 THP-l Blue cells, maintained at 37°C, 5% CO2 in RPMI supplemented 
with heat inactivated FBS, 100u/ml penicillin G and 100Jlg/ml streptomycin and 
200Jlg/ml zeocin, were stimulated with FimA, Mfal or TLR agonists in 96 well plates for 
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24hrs. Nf-KB activation was quantified by using the QUANTI-Blue assay, according to 
the manufacturer's protocol. 
TLR2 surface expression following FimA stimulation: 
PBMCs (1 xl06 cells) were treated with FimA (lllg / ml) or left unstimulated for 
24hrs. Surface· expression or redistribution of TLR2 was quantified by flow cytometry 
using FITC-conjugated anti-TLR2 and istoype control antibodies. 
Involvement ofIRAK-l, in FimA-induced TLR2 tolerization: 
Whole cell lysates from 2.5 million PBMCs stimulated with 1 Ilg/ml FimA, and 
unstimulated controls, were prepared using RIP A lysis buffer with a phosphatase and 
protease inhibitor cocktail. Total protein was determined by BCA assay according to the 
manufacturer's protocol. Western blots (30 Ilg protein) were probed for IRAK-l, IRAK-
M, IKBa and ~-actin. Immunoreactive bands were visualized by chemiluminescence. 
Image analysis and densitometry were performed using the Kodak 4000MM Image 
Station. Band intensities were normalized to the loading control (~-actin) and expressed 
as relative intensities. 
Statistical analysis: 
All experiments were carried out a minimum of three times, unless otherwise 
noted. Statistical significance between groups was evaluated by one-way nonparametric 
ANOYA and the Tukey multiple-comparison test using the InStat program (Graph-Pad 
Software, San Diego, CA). Differences between groups were considered significant at the 
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level of P < 0.05. 
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CHAPTER THREE: TOBACCO-INDUCED ALTERATIONS TO P. 
GINGIVALIS-HOST INTERACTIONS. 
Introduction 
Cigarette smokers, and those exposed to secondhand smoke, are more susceptible 
to multiple infectious diseases than unexposed individuals (58, 223-227). Tobacco 
smoking is considered to be a major environmental risk factor for periodontitis, a 
common infectious oral disease that results in detachment of the gingival tissue cuff, 
destruction of the collagen attachment to the root surface of the tooth, and resorption of 
the supporting alveolar bone. Patients who smoke exhibit not only increased 
susceptibility to periodontitis but are also more likely than non-smokers to display severe 
disease and to be refractory to treatment (88). Although periodontitis is caused by a 
polymicrobial infection of the gingiva, the Gram negative, anaerobic bacterium, 
Porphyromonas gingivalis, has been strongly associated with diseased sites in the oral 
cavity and is considered to be a causative agent of chronic periodontitis (146, 228). In 
addition, P. gingivalis infection elicits systemic inflammation (229) and may increase 
susceptibility to systemic vascular diseases (230, 231). Multiple studies have shown that 
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smokers are more likely to be infected with P. gingivalis, to harbor higher numbers of 
P. gingivalis, and to exhibit more persistent infection (138-141, 147) relative to non-
smokers. 
Despite increased P. gingivalis infection rates and susceptibility to disease 
progression, smokers consistently display reduced clinical inflammation, measured as 
angiogenesis, edema, inflammatory index, and/or gingival bleeding compared to non-
smokers (86, 88, 133, 203, 232). Smokers also exhibit lower levels of pro-inflammatory 
cytokines at diseased sites (233-237). This represents a clinical conundrum to oral health 
professionals who must diagnose periodontal diseases, and a scientific enigma to those 
attempting to understand the mechanisms underlying tobacco-induced and / or 
exacerbated periodontitis. 
It is known that tobacco smoke and specific smoke components and/or 
metabolites can exert a profound negative influence on the host response (86, 88, 217, 
238-241). For example, previous work in the lab in myelocytic cells demonstrated that 
nicotine and/or its primary metabolite, cotinine, suppresses the pro-inflammatory 
cytokine response to P. gingiva lis while promoting the release of the anti-inflammatory 
cytokine IL-l 0 (241). Nicotine also suppresses the production of reactive oxygen species 
in response to Gram negative stimuli, concomitant with a reduced capacity to kill 
phagocytosed P. gingivalis cells (242). 
In contrast to what is known about host responses, there are essentially no data 
available on how components in cigarette smoke may influence the organisms that 
comprise the oral microbial biofilm. Thus, it is possible that smoking not only 
influences the host response but also the organisms in the dental biofilm and that the 
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increased severity of periodontitis in smokers may be attributed to both of these effects. 
We hypothesized that cigarette smoke extract (CSE) represents an environmental stress 
to P. gingiva lis and that the organism adapts to this stress by altering its pattern of gene 
expression. In this report, we show that the pro-inflammatory response of primary 
human peripheral blood mononuclear cells (PBMCs) against P. gingivalis is significantly 
reduced when the bacteria are pre-treated with CSE and that this effect was reversed 
when CSE treated bacteria were sub-cultured in fresh growth medium without CSE. The 
response of P. gingivalis to CSE exposure was examined using both biochemical and 
molecular biologic approaches. Numerous genes, including those encoding outer 
membrane proteins and virulence determinants were differentially expressed upon CSE 
exposure. These results may explain at least in part the altered virulence and host-
pathogen interactions associated with cigarette smoking. 
Results 
P. gingivalis growth in eSE-conditioned medium: 
To determine if a physiologically relevant dose of CSE (500 ng mr! nicotine 
equivalents [see Experimental Procedures]; (214-217) was overtly toxic to P. gingivalis 
W83 cells, we compared the growth rates of bacteria in CSE-conditioned and non-
conditioned medium. As shown in Figure 3, similar growth characteristics were observed, 
suggesting that P. gingivalis W83 tolerates this level of CSE. Thus, for all subsequent 
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Figure 3. Effect of CSE on P. gingivalis growth: Typical growth curves of P. 
gingivalis W83 in CSE conditioned and unconditioned medium. Growth of P. 
gingivalis was compared in GAM medium and GAM conditioned with CSE (500 ng 
ml-l nicotine equivalents). Closed triangles represent growth in GAM. Open triangles 
represent growth in GAM-CSE. Error bars represent the mean (SD) of three 
experiments. There were no significant differences in the growth characteristics of P. 
gingivalis cultured in GAM or GAM-CSE (P>O. 05). 
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Figure 4. Reversible suppression ofTNF-a release from human monocytes: 
(A) Primary human monocytes (0.5 x 106) were stimulated with 106_109 cells of 
control P. gingivalis (black bars) or GAM-CSE (white bars) for 20h and TNF-a 
levels determined in cell-free supernatants by ELISA (** represents P < 0.01). (B) 
Reconditioning of P. gingivalis in GAM rescuses pro-inflammatory potential: 
Primary human monocytes (0.5 x 106) were stimulated for 20 h with GAM-
cultured P. gingiva lis (Black bars), CSE-treated P. gingivalis, or P. gingivalis cells 
that were first grown in GAM-CSE for two passages then reconditioned in 
untreated GAM for two passages (107 P. gingivalis cells). TNF-a levels were 
determined in cell-free supernatants by ELISA (** represents P < 0.01). 
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Induction of TNF -(l release from PBMCs by CSE-exposed P. gingivalis: 
Evidence from in vivo studies in humans have shown that smokers exhibit 
reduced clinical inflammation in response to pathogenic plaque bacteria (88, 203) and 
exhibit decreased gingival crevicular fluid (GCF) concentrations of major pro-
inflammatory mediators, such as TNF-a and IL-I (233-237) and increased GCF levels of 
anti-inflammatory cytokines including IL-IO and TGF-pi (235, 243). To determine if 
exposure of P. gingivalis to CSE alters its inflammatory potential, primary human 
PBMCs were challenged with control and CSE-treated bacteria. As shown in Figure 4a, 
the release of TNF-a was significantly lower when PMBCs were incubated with CSE-
treated bacteria. Interestingly, when CSE-treated organisms were sub-cultured in 
fresh growth medium without CSE, their inflammatory potential increased back to the 
level of untreated bacteria (Figure 4b), suggesting that the CSE-induced effect is 
reversible. Thus, P. gingiva/is appears to reversibly respond to CSE as an 
environmental stress. The production of multiple pro inflammatory cytokines (TNF-a, 
IL-6 and IL-12 p40) by CSE-exposed and control P. gingivalis was also screened in 
PBMCs. Production of TNF- a and IL-12 p40 was reduced in PBMCs stimulated with 
CSE-exposed bacteria compared with untreated P. gingivalis controls and, again, the 
inflammatory potential of P. gingivalis was restored on reconditioning in fresh GAM 
(Fig. 5). 
P. gingivalis genes up-regulated on eSE-exposure: 
In order to further characterize the response of P. gingivalis to CSE-exposure, we 
performed microarray analyses to identify genes that are differentially expressed in CSE-
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treated versus control bacteria. A total of 104 genes (approximately 4.7% of the P. 
gingivalis genome) were found to be differentially expressed by 2-fold or more (p < 
0.05); 58 genes were induced and 46 were suppressed upon CSE treatment (see Figure 6). 
Of the 58 genes that were induced by CSE treatment, multiple genes within several 
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Figure 5: Reversible suppression of multiple proinfiammatory cytokines in 
human PBMes stimulated with eSE-treated P. gingivalis. Primary human 
PBMCs (0.5 x 106) were stimulated for 20 h with GAM-cultured P. gingivalis, 
CSE-treated P. gingivalis, or P. gingivalis cells that were first grown in GAM-CSE 
for two passages then reconditioned in untreated GAM for two passages (107 P. 
gingivalis cells). PBMCs stimulated with reconditioned P. gingivalis produced 
levels of (A) IL-12p40 (B) TNF-a (e) IL-6, that were similar to PBMCs that were 
stimulated with bacteria from control cultures (not exposed to CSE). Error bars 
represent the mean (SD) of three experiments. One asterisk (*) indicates statistical 
significance at P < 0.05; double asterisks (**) indicate statistical significance at P 
< 0.01. 
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by TIGR) were identified, including the major fimbrial operon (2 genes), an operon 
encoding outer membrane antigenic lipoproteins (4 genes); the transfer (tra) gene cluster 
(4 genes) and an operon encoding an ABe transporter of unknown function [PG0682 -
PG0685; 3 genes]. Within the eSE-induced genes, several functional families 
predominate. One group of genes encode proteins that may be involved in DNA 
replication and repair (e.g. ruvC [PG 1324, holliday junction endonuclease]; PG0817 
encoding a putative integrase; and radC [PG0894, DNA repair protein]) or in the 
insertion and transposition of genetic material (e.g., traE [PG1483]; traF [PG1482]; and 
traK [PG1478], each encoding proteins associated with a conjugative transposon). 
Several other transfer genes (traG [PG1481] and traQ [PG1473]) from this same region 
of the P. gingivalis genome were differentially expressed but fell just below the 2-fold 
limit used in the analysis. In addition, several of the insertion sequences that are present 
in the P. gingivalis genome were differentially expressed (ISPg3 [PG0299]; ISPg5 
[PG0943]; ISPg6 [PGI061]. 
A second group of eSE-induced genes encode proteins involved in potential 
pathogen-host interactions and virulence. These include several proteases (encoded by 
tpr, trpT and PG0317), an efflux transporter (PG0283) related to the bacterial secretion 
system I protein HlyD, and a putative polysaccharide transport protein related to 0-
antigen flippase (PG0912). In addition, two genes encoding putative lipoproteins 
(PG2133 and PG2134) that are required for the assembly of the major fimbriae of P. 
gingivalis (244) were induced by eSE. These genes are co-expressed withfimA encoding 
the fimbrial subunit protein. Several other genes encoding cell surface or outer 
membrane polypeptides were also differentially expressed including the co-expressed 
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Figure 6. Porphyromonas gingivaiis genes up-regulated following CSE 
exposure. The microarray data of Log2 ratios were uploaded onto 
MultipleExperiment viewer 4.1v (January 8, 2008 release) software and evaluated 
by (-test with P-value based on'!, distribution with significance (alpha cut-off) set 
at P < 0.01. The subset of significant genes was divided into two groups based on 
(i) upregulated genes (> 1.5-fold increase) and (ii) downregulated genes « 0.5-
fold). The distance was calculated based on Euclidean distance with average 
linkage and the tree was generated based on hierarchical clustering. Cigarette 
smoke extract-induced genes (significantly induced genes> 1.5-fold compared 
with baseline; P < 0.01 are represented in yellow to blue colour with the lower 
limit = 1.5; midpoint value = 2.5; and upper limit = 5. 
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Figure 7. Porphyromonas gingiva/is genes down-regulated following CSE 
exposure. The rnicroarray data of Log2 ratios were uploaded onto 
MultipleExperiment viewer 4.1 v (January 8, 2008 release) software and evaluated 
by (-test with P-value based on't' distribution with significance (alpha cut-off) set 
at P < 0.01. The subset of significant genes was divided into two groups based on 
(i) upregulated genes (> I.S-fold increase) and (ii) downregulated genes « 0.5-
fold). The distance was calculated based on Euclidean distance with average 
linkage and the tree was generated based on hierarchical clustering. Cigarette 
smoke extract-suppressed genes (significantly downregulated genes < O.5-fold 
compared with baseline; P < 0.0 I) are represented in yellow to blue colour with 
the lower limit = 0.1; midpoint value = 0.4; and upper limit = 0.5. 
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major immunoreactive 61 and 63 KDa surface antigens encoded by PG2102 and PG2100, 
respectively, putative lipoproteins (PGI233, PG1234 and PG0722), and an outer 
membrane TonB-dependent receptor (PG200S). Other genes were differentially 
expressed but fell just below the 2-fold limit used in the analysis, including the lpt-l 
(ptp 1, PG 1641) gene that has recently been shown to be a multifunctional regulator of 
virulence (245). 
To verify the results of the microarray experiments, the expression of select genes 
from the array dataset were analyzed by RT-PCR. As shown in Table 2, the RT-PCR 
results of selected genes that were tested were consistent with the increased expression of 
these genes observed in the microarray analyses of CSE-treated cells. 
P. gingivalis genes down-regulated on eSE-exposure: 
Many of the 46 genes (2.1 % of the P. gingivalis genome) that were suppressed 
by two-fold or more (p < 0.05) encode hypothetical proteins (see Figure 7) whose 
functions have yet to be determined. However, two genes in the capsular biosynthesis 
locus (246) were down-regulated - a putative capsular polysaccharide synthesis gene 
(capK, PGOll1) and a polysaccharide transport protein related to a flippase (PG0117). 
The expression of two other genes in the capsular biosynthesis locus, encoding a 
glycosyltransferase (PGO lIS) and a UDP-N-acetyl-D-mannosaminuronic acid 
dehydrogenase (wecC, PGO lOS) were down-regulated just below the 2-fold limit used in 
the analysis. Also down-regulated in response to CSE was a sensor histidine kinase 
(jimS) which together with the co-expressed response regulator FimR has been reported 
to regulate the expression of the major and minor fimbrial operons of P. gingivalis (247). 
Lastly, the expression of hmuR (PG 1552) encoding a tonB-dependent hemoglobin 
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receptor HmuR was reduced by approximately 2-fold by CSE treatment. Selected down-
regulated genes were analyzed by RT-PCR (see Table 2) with consistent results. 
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a. The 1. Craig Venter Institute annotations; b. > l.5, < 2.0-fold change in gene activity; 
c. Reduced activity not reaching threshold « 1.5-fold). 
CSE alters expression of P. gingivalis outer membrane proteins RagA and RagB: 
In addition to the transcriptome analysis described above, a membrane fraction 
that was enriched for P. gingivalis outer membrane proteins was isolated from CSE-
treated and control cells and analyzed by SDS gel electrophoresis. As shown in Figure 8, 
the Triton X-I00 insoluble membrane fraction contained approximately ten major 
polypeptide bands, of which three were clearly overrepresented in the extract from CSE-
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treated bacteria. These bands were excised from the gel and analyzed by MALDI-MS 
after digestion with trypsin. Tryptic peptides were identified for the RagA (43% 
sequence coverage), RagB (66% coverage) and a putative lipoprotein (pG0179, 53% 
coverage) that is likely co-expressed with the minor fimbrial antigen of P. gingivalis 
(248). Interestingly, western blots of RagB proteins revealed that reconditioning of P. 
gingivalis in GAM, following culture in GAM-CSE, resulted in RagB expression levels 












Figure 8: Up regulation of specific outer membrane protein in CSE-
exposed P. gingivalis. Outer membrane proteins of P. gingivalis grown in 
GAM and GAM-CSE were isolated by differential extraction with Triton X-
I 00. 20~g of total outer membrane protein extracts was run through a 4-15% 
gradient gel. MALDI-MS of excised bands followed by comparison with the 
open reading frame database of P. gingivalis W83 from The J. Craig Venter 
Institute identified the major CSE upregulated bands, as shown. 
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Figure 9: Cigarette smoke extract-induced RagB upregulation in P. 
gingivalis is reversible. A typical Western blot of RagB in lysates of cells 
sequentially passaged in GAM, GAM-CSE and GAM, respectively, is 
shown. Culture in GAM-CSE resulted in an increase in relative RagB 
expression levels (147%). Relative RagB expression returned to near control 
levels on reconditioning in GAM. 
Discussion 
Cigarette smoking increases vulnerability to P. gingivalis infection and increases 
susceptibility to periodontitis, but reduces clinical signs of overt inflammation. The 
mechanisms that cause the apparent dichotomy between increased infection by P. 
gingivalis, increased severity of disease, but reduced inflammatory response in smokers 
remain to be determined. Our results provide some of the first information to explain 
such phenomena and are consistent with many previous in vivo observations. 
We show that P. gingivalis exposed to physiologic concentrations of CSE induce 
a significantly lower pro-inflammatory response from PMBCs than control cultures 
grown without CSE. Furthermore, this effect is reversed when CSE-treated bacteria are 
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sub-cultured in medium without eSE, suggesting that eSE exposure may represent an 
environmental stress that P. gingivalis is able to specifically respond to. Thus, the 
reduced inflammatory potential of eSE-exposed P. gingivalis cells represents a 
mechanism that may contribute, at least in part, to the reduced inflammation observed in 
periodontitis patients who smoke. 
Such a reduced P. gingivalis-elicited inflammatory response is likely to aid these 
bacterial cells in immune evasion which, in tum, would help explain the increased levels 
of P. gingivalis infection and reduced clearance rates noted in smokers compared to non-
smokers (138-141, 147). 
Our results showing suppressed TNF -u induction from innate cells by smoke-
exposed P. gingivalis are also in keeping with several in vivo reports of reduced levels of 
pro-inflammatory cytokines at diseased sites (233-237). Furthermore, the upregulation of 
several virulence factors in the periodontopathogen, P. gingivalis, are in keeping with the 
increased disease severity known to occur in smokers compared to non-smokers. Specific 
dysregulated virulence factors are discussed further below. 
Our results clearly show that the response of P. gingivalis to eSE exposure is 
varied and genome wide. Approximately 7% of the genes in the P. gingivalis genome 
were found to be differentially expressed by transcriptome analyses. Furthermore, a 
number of the differentially expressed genes have been associated with aspects of P. 
gingivalis virulence. Several functionally-related genes were dysregulated, including 
multiple genes in the major fimbrial and capsular polysaccharide operons, as well as 
genes encoding transcriptional regulators; efflux pump and transport proteins; proteases 
and cell envelope proteins. The major fimbriae have been shown to be important for 
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numerous aspects of P. gingivaZis virulence, including bacterial adhesion and invasion of 
epithelial and endothelial cells (Lamont & Jenkinson, 1998 and 2000). PG2133 and 
PG2134 encode putative lipoproteins that are co-expressed with FimA, the major fimbrial 
subunit protein. Wang et al. recently showed that inactivation of these genes results in 
the expression of significantly shorter fimbriae, suggesting that these putative 
lipoproteins play an essential role in fimbrial biogenesis. The mutant strains also 
exhibited reduced invasion and intracellular persistence in macrophages and were less 
virulent in a mouse model of periodontitis (244). 
There are at least six different capsular serotypes (K 1 to K6) expressed by P. 
gingivalis and altered virulence has been associated with K+ and K strains (195, 249-
251). While the contribution of P. gingivalis capsule to inflammation is poorly 
understood, recent evidence shows that capsular polysaccharide from several strains of P. 
gingivalis, including W83 elicits a substantial pro-inflammatory cytokine response from 
murine innate cells (252). The down regulation of several genes in the capsular 
biosynthesis operon (PGO 111 and PGO 117) suggests that capsule synthesis may be 
reduced upon exposure to eSE, consistent with the reduced inflammatory potential of 
eSE-treated bacteria. 
In addition to the differential expression of genes described above, several other 
cell surface or outer membrane proteins, i.e., RagA, RagB and PGO 179 were shown by 
biochemical approaches to be present at higher levels after CSE treatment. Interestingly, 
the genes encoding for these components were not identified as being differentially 
expressed in the micro array experiments. This suggests that post-transcriptional events 
may also be involved in the response to eSE, or alternatively may reflect inherent 
50 
limitations in the microarray approach. Each of the differentially expressed proteins has 
been associated with aspects of P. gingivalis virulence. The ragAB locus was likely 
acquired by horizontal gene transfer (253). RagA is a putative tonB-dependent outer 
membrane receptor whereas RagB is an immunodominant lipoprotein. Both genes have 
reported to be up-regulated under conditions of thermal stress (254) and both represent 
significant P. gingivalis virulence factors (255, 256), although their specific contribution 
to periodontal disease remains to be determined. However, it is interesting that the RagA 
homolog (designated OmpA) from the closely related bacterium Bacteroides caccae has 
been associated with inflammatory mucosal (bowel) disease (257). PG0179 is a gene that 
is co-expressed with the minor fimbrial antigen (mia]). The minor fimbriae playa key 
role in P. gingivalis autoaggregation (174) and are critical mediators of the interspecies 
interactions between Porphyromonas gingivalis and oral streptococci that facilitate 
biofilm formation (173, 218, 258). Thus, stimulation of the minor fimbrial operon by 
CSE may facilitate increased P. gingivalis colonization of the periodontia. 
Lastly, a number of genes that were differentially expressed encoded proteins 
involved in DNA replication, DNA repair and the transfer or mobilization of genetic 
material. Comparison of the recently completed genome sequence of P. gingivalis A TCC 
33277 with that of strain W83 indicates that mobile genetic elements have contributed 
greatly to genomic diversity among P. gingivalis strains (Naito et aI., DNA Res. 2008). 
The up regulation of transfer genes and several insertion sequence elements in CSE-
exposed cells suggests that the environmental stress imposed by cigarette smoke may 
stimulate genetic rearrangements. In addition, considering the highly carcinogenic 
potential of cigarette smoke, the up-regulation of DNA-repair and -control genes is not 
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surprising. Cigarette smoke is also a major oxidative stressor (259, 260). A single 
cigarette is estimated to contain 1016 oxidant molecules (261). Thus, the up regulation of 
ferritin [PO 1286], an iron sequestrator, may provide protection against free-iron-related 
oxidative stress (262). In addition, the response regulator, RprY (also up regulated after 
CSE treatment) has recently been shown to be responsive to reactive oxygen species and 
iron (263). It is also interesting to note that several other anti-oxidant genes were 
differentially expressed (p<0.05) when the threshold for induction in the array experiment 
was reduced from 2-fold to 1.5-fold. In addition, the up-regulation of efflux pump and 
other ABC transport systems may confer resistance to potentially harmful chemicals 
present in CSE. Taken together, these results suggest that CSE may represent a potent 
environmental stressor that induces a protective response from P. gingivalis. 
In summary, smokers are more prone to infection with P. gingivalis and to 
develop periodontitis, yet exhibit reduced clinical inflammation. Consistent with this, we 
have found that CSE-exposed P. gingiva lis exhibits a reduced capacity to elicit an 
inflammatory response from immune cells. P. gingivalis responds globally to CSE 
exposure and multiple virulence associated genes are differentially expressed. These 
results may explain in part the altered virulence and host-pathogen interactions that occur 
in smokers with periodontal disease and provide some of the first information illustrating 
how P. gingiva lis responds at the molecular level to cigarette smoke. 
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CHAPTER FOUR: TOBACCO UPREGULATES P. GINGIVALIS 
FIMBRIAL PROTEINS THAT INDUCE TLR2 HYPOSENSITIVITY. 
Introduction 
Tobacco smokers are more susceptible than non-smokers to multiple infectious 
diseases, particularly mucosal infections such as tuberculosis, pneumonia, Chlamydiasis, 
gonorrhoea, otitis media and periodontitis (264). The mechanisms underlying such 
increased susceptibility are not well understood. Several groups have shown that tobacco 
smoke as well as individual smoke components induce physiological and structural 
changes, e.g. reduction of mucociliary clearance (265, 266), and dysregulate specific 
elements of immune function, e.g. inhibition of the respiratory burst and phagocytosis 
(242, 267, 268) and interference in antigen presentation (269, 270). However, the 
influence of tobacco on bacterial virulence is - essentially - unstudied. 
Periodontitis is a bacteria-induced, irreversible chronic inflammatory mucosal 
disease characterized by the destruction of the soft and hard supporting structures of the 
teeth. Tobacco smokers are more susceptible than non-smokers to infections with 
periodontal pathogens (264) and are more likely to develop severe periodontitis and to 
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prove refractory to treatment (88). Paradoxically, smokers show reduced clinical signs of 
inflammation in response to dental plaque than non-smokers, particularly the key 
diagnostic indices of gingival bleeding on probing and edema (88, 203). Again, the 
mechanisms underlying this phenomenon are poorly characterized. 
Porphyromonas gingivalis, a Gram negative, asaccharolytic anaerobe, is a key 
periodontal pathogen whose numbers are increased in tobacco smokers (88, 203). There 
is some evidence that components of tobacco smoke augment P. gingivalis pathogenesis. 
Nicotine and its primary metabolite - cotinine - have been shown to increase the lethality 
of cell-free extracellular toxins and cell lysates from P. gingivalis in the chick embryo 
model (271, 272). The combination of benzopyrene, a tobacco smoke aryl hydrocarbon, 
and P. gingivalis lipopolysaccharide (LPS) significantly increase the inhibition of 
osteogenesis in a rat bone marrow cell model, compared to either agonist alone (273). 
We have recently shown that P. gingivalis adapts to the environmental stress 
presented by cigarette smoke extract (CSE) by altering the expression of several genes 
and outer membrane proteins (274). Concomitant with this adaptive response to CSE, P. 
gingivalis induces a lower inflammatory response (TNF-a, IL-6 and IL-12 p40) from 
human innate cells compared to unexposed, control bacteria (274). Furthermore, the 
inflammation-inducing potential of P. gingivalis is restored when cells are sub-
cultured back into fresh medium without CSE. Interestingly, microarray analyses 
determined that specific genes (PG2133 and PG2134) in operons coding for the synthesis 
and assembly of major and minor fimbrial antigens (FimA and Mfal) of P. gingivalis 
were induced on exposure to CSE, while several genes in the capsular biosynthesis locus 
(capK, PGOI17, PGOl18 and wecC) were suppressed (274). 
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It is important to note that capsule polysaccharides and major fimbrial protein will 
be the two P. gingivalis features that first engage the host response and, thus, are likely to 
play critical roles in directing initial host-pathogen interactions. Capsule production is 
associated with tissue invasiveness (195) and has been reported to be inversely related to 
biofilm growth (275), while capsular polysaccharides represent potent cytokine-inducing 
stimuli (252). The major fimbrial antigen or FimA is also an important virulence factor 
that facilitates the adhesion and initial attachment of P. gingivalis to junctional epithelial 
cells, thus aiding sub-gingival colonization (276). FimA appears to signal via TLR2 and 
induces the expression of several pro-inflammatory cytokines such as TNF-a, IL-6 and 
IL-l~ in innate immune cells (150). However, the potency of FimA as a pro-
inflammatory agonist is controversial (157, 168, 277, 278). Thus, alterations in P. 
gingivalis capsule and fimbriae production would be expected to exert marked effects on 
virulence and host-pathogen interaction. 
We hypothesized that CSE-regulation of capsule and fimbrial genes is reflected at 
the ultrastructural and functional levels, alters the nature of host-pathogen interactions, 
and contributes to the reduced pro- inflammatory potential of smoke exposed P. 
gingivalis. We establish that CSE up-regulates P. gingivalis FimA at the protein level, 
suppresses the production of capsular polysaccharides at the ultrastructural level, and 
creates conditions that promote biofilm formation. We further show that while FimA is 
recognized by TLR2/6, it has only minimal inflammatory activity in several cell types 
(PBMCs, neutrophils, and epithelial cells) and, furthermore, FimA stimulation 
chronically abrogates the pro-inflammatory response to subsequent TLR2 stimulation by 
other TLR2-specific agonists (Pam3CSK4, Mfal) in an IRAK-l-dependent but NF-KB-
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independent manner. These studies provide some of the first information to explain, 
mechanistically, how tobacco smoke changes the P. gingivalis phenotype in a manner 
likely to promote P. gingivalis colonization and infection while simultaneously reducing 
the host response to this major mucosal pathogen. 
Results 
Tobacco smoke exposure alters expression of P. gingivalis fimbriae and capsule: 
Our previous microarray data indicated that eSE induced the expression of genes 
key to the synthesis and assembly of FimA (PG2133 and PG2134), concomitant with a 
suppression expression of several genes in capsular biosynthesis locus (capK, PG0117, 
PGOl18 and wecC) (274). We now show that eSE-exposure reversibly increases FimA 
protein, as shown in Figures lOA and B. Transmission electron micrographs clearly 
establish that these eSE-regulated transcriptional and translational activities are reflected 
at the ultrastructural level, as shown in Figures 10C and 10D. Furthermore, eSE-induced 
FimA is both surface exposed, as assessed by availability to FimA-specific antibodies 
(Figure 10F) and functional, as assessed by binding to the established FimA ligand -
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Figure 10: CSE induces phenotypic surface changes in P. gingivalis. (A) Typical 
Western blot ofFimA in Iysates of lxl06 p , gingivalis cells sequentially passaged 
in GAM, GAM-CSE, and then fresh GAM, respectively. (B) Typical relative band 
intensities establish that FimA expression is increased on CSE-exposure, but that 
FimA expression reverts to control levels upon sub-culturing P. gingivalis back into 
fresh GAM. Representative transmission electron images of P. gingivalis grown in 
GAM (C) or GAM-CSE (D). The black arrow indicates the p, gingivalis capsule, 
which is greatly reduced in presence of CSE. These CSE-induced phenotypic 
changes are concomitant with an increased binding of P. gingivalis to the FimA 





Figure 11: Visualization of homotypic biofilm formation by P. gingivalis 
grown in GAM or CSE. 48 hr P. gingiva/is biofilms, formed in an open flow 
system, were stained with FITC. Optical sections were obtained along the x-y 
and z axis at 1 J.1tll intervals. (A) and (B) are representative images ofbiofilms 
formed in GAM or GAM-CSE, respectively. Top panels represent x-y images 
while the bottom panel shows x-z stacks, reflecting biofilm thickness formed 
in GAM or GAM-CSE, respectively. Z-stack images were obtained from 5 
randomly selected fields per biofilm and image data recorded along the x-y-z 
planes. 
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CSE augments P. gingivalis biofilm formation: 
Biofilms play an important role in the pathology of periodontal disease by 
mechanisms that include protection of plaque bacteria against phagocytosis and against 
antibiotics (249). FimA plays a critical role in P. gingivalis biofilm formation. Indeed, P. 
gingivalis strains lacking FimA cannot form biofilms (279). Furthermore capsule 
synthesis has been shown to inversely correlate with biofilm growth (275). To establish if 
our initial discoveries that CSE upregulates FimA production but downregulates capsule 
production (274) influence biofilm formation, CSE-exposed and unexposed P. gingivalis 
was grown in an open flow biofilm system. Representative biofilm images are presented 
in Figure IIA-B. There was a significant increase in overall homotypic biofilm formation 
in the presence of CSE (Table 3), with increased biomass, substratum coverage, 
maximum and mean thickness apparent (allp < 0.01). 
Table 3: Quantitative characteristics of P. gingivalis biofilms 
48h Biofilm Biomass Substratum Average 
(J.1m3/J.1m2) coverage (J.1m2) thickness (J.1m) 
P. gingivalis GAM 1.869 ± 1.15 0.315 ± 0.11 2.505 ± 0.443 
.----< 
P. gingivalis GAM-CSE 5.708 ± 0.38*** 0.679 ± 0.06 12.66 ± 
1.487** 
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Figure 12: Inflammatory potential of rFimA and rMfal. 0.5x106 primary human 
PBMCs were stimulated with 1 Ilg/ml ofrFimA, rMfal or the TLR2 and -4 specific 
agonists Pam3CSK4 and E. coli LPS, respectively. (A) TNF-a; (B) IL-6; and (C) 
IL-I0 release was quantified by ELISA in 20 hr cell-free supernatants, harvested by 
centrifugation. (D) 0.5xl 06 primary human neutrophils were stimulated with 1 
Ilg/ml ofrFimA, rMfal , Pam3CSK4 or E. coli LPS. IL-8 release was quantified in 
20 hr cell-free supernatants by ELISA.(E) Confluent OBA-9 epithelial cells 
(0.46106) were stimulated with 1 Ilg/ml of rFimA, rMfal , Pam3CSK4 or E. coli 
LPS. IL-8 release was quantified in 20 hr cell-free supernatants by ELISA. (F) 
Similar to purified FimA, whole, CSE exposed P. gingivalis also induced increased 
IL-I0 secretion from primary human PBMCs compared to control bacteria. *p < 
0.05 ; **p < 0.01 ; ***p < 0.00l. 
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FimA and Mfal exhibit differential pro-inflammatory potential: 
While the innate response to the major fimbrial antigen of P. gingivalis, FimA, 
has been partially characterized (45) the inflammatory potential of the minor fimbrial 
antigens (Mfal) are not well understood. Therefore, to better understand the relevance of 
CSE-upregulation of FimA and Mfa 1 , particularly in the context of the reduced 
inflammatory response to plaque that is consistently observed in human smokers (280), 
we quantified the cytokine production elicited by these predominant, CSE-regulated 
surface antigens in PBMCs (Figure 12A-C), neutrophils (Figure l2D) and gingival 
epithelial cell line OBA-9 (Figure 12E). While FimA did promote a cytokine response 
from each cell type tested, the concentration of pro-inflammatory cytokines induced 
(TNF -a; IL-6; IL-8) was minimal when compared to the classic bacterial-derived pro-
inflammatory agonists, LPS and Pam3CSK4. In contrast, FimA did induce high levels of 
the anti-inflammatory cytokine, IL-I0 (Figure 12C). Mfal, on the other hand, induced a 
robust pro-inflammatory response that was comparable or greater in magnitude to that of 
LPS in PBMC's (Figures 12A and 12B), neutrophils (Figure 12D) and epithelial cells 
(Figure 12E). These results are similar to those seen with intact bacteria. We have 
previously shown that whole, smoke-exposed P. gingivalis exhibit reduced inflammatory 
potential than control (unexposed) cells, as measured by decreased induction of multiple 
pro-inflammatory cytokines (TNF-a, IL-6 and IL-12 p40) (281). We extend these 
observations to show that CSE-exposed P. gingivalis induce increased IL-lO in innate 
cells, compared to unexposed bacteria (Figure 12F). 
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FimA and Mfal are TLR2-specific agonists: 
In order to understand the differential pro-inflammatory potential of FimA and 
Mfal at the mechanistic level, we first established the TLR-specificity of each of these 
two specific CSE-dysregulated P. gingivalis surface proteins. IL-8 production by rFimA 
or rMfal stimulated HEK293 cells stably expressing variant TLRs was quantified. As 
shown in Figure 13A, significantly higher levels of IL-8 were produced by HEK clones 
expressing TLR211 and, particularly, TLR2/6 compared to all other clones (both p > 
0.001). 
As FimA induced lower levels of pro-inflammatory cytokines in innate immune 
cells than Mfal we hypothesized that FimA may not be a strong activator of NF-KB. 
However, in the THP-l blue cell model, FimA and Mfal each proved to be effective 
































Figure 13: rFimA and rMfal signal preferentially through TLR2/6. (A) HEK 293 
cells stably expressing TLR2, 4, 211, 2/6 or TLR4-CD 14-MD2 were stimulated with 1 
J.!g/ml of rFimA, rMfa 1, the classic TLR2-specific agonist, Pam3CSK4 or the classic 
TLR4-specific agonist E. coli LPS. IL-8 release was quantified in 20 hr cell-free 
supernatants by ELISA. n.d. = not detected (below assay threshold); *p< 0.05; 
**p<O.O 1; ***p<O.OO 1. (B) THP-l Blue cells were stimulated with 1 J.!g/ml of rFimA, 
rMfal, Pam3CSK4 or E. coli LPS. Relative expression levels of SEAP (reflecting NF-
kB) in cell-free supernatants were determined by spectrophotometric analysis of SEAP 
activity at 655 nm. Unstimulated cells represent the 100% control. Here we show that 
all TLR-agonists employed are equally capable of inducing NF-kB. ***p< 0.001 
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Figure 14: FimA induces TLR2-specific innate tolerance. 0.5xl06 primary human 
PBMCs were pre-incubated with rFimA for 24 hrs before stimulation with 1 f.lg/ml of 
rFimA, rMfal or the TLR2 and -4 specific agonists Pam3CSK4 and E. coli LPS. 
Responses were compared to cells treated with the same agonists without any pre-
incubation. (A) TNF-a; (B) lL-6. n.d. = not detected (below assay threshold); ***p< 
0.001. 
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FimA induces TLR2-specific innate tolerance: 
We next examined if exposure to low-activity FimA influenced cytokine 
production (lL-6, TNF-a) in PBMCs on subsequent TLR stimulation by potent pro-
inflammatory agonists (Mfal and the TLR2/1 and TLR2/6 specific agonists, Pam3CSk4 
and FSL respectively). Pre-incubation with FimA inhibited cytokine production in 
response to all TLR2 specific agonists tested, as shown in Figure 14. Thus, FimA induces 
a state of inflammatory hypo-responsiveness in PBMCs. TLR2 surface expression by 
PBMCs in response to FimA stimulation was monitored by flow cytometry. There was no 
significant difference in TLR2 surface expression levels up to 24hrs post-FimA 
engagement (data not shown). Thus, FimA stimulation does not alter surface expression 
of TLR2 in PBMCs. 
FimA stimulation does not induce IKBa degradation but inhibits IKBa degradation 
by Mfal: 
NF-KB transcription factors are complexed with IKB proteins in the cytosol. On 
receiving specific, but varied, extracellular signals IKBa is phosphorylated and targeted 
for proteasome-mediated degradation, resulting in the release and nuclear translocation of 
transcriptionally effective NF-KB (82, 88, 203, 232, 282, 283). We compared IK-Ba 
protein levels in PBMCs exposed to rMfal, with or without pre-incubation with rFimA. 
As shown in Figure 15, while the potent pro-inflammatory agonist, Mfal, induced rapid 
and extensive IK-Ba degradation, pre-incubation with rFimA efficiently abrogated this 
Mfal-triggered IK-Ba degradation. Thus, FimA appears to promote TLR2 hyposensitivity 
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by inhibiting TLR2 agonist-induced degradation of IK-Bu. Essentially identical results 
were found for a second TLR2 agonist, FSL (data not shown). 
FimA induced innate tolerance is lRAK-l-mediated: 
To further understand mechanisms underlying FimA-induced TLR hypo-
responsiveness, we monitored cytosolic IRAK-M and IRAK-l in PBMCs. In 
unstimulated PBMCs, exposure to TLR2 agonists resulted in the rapid (within minutes) 
degradation of the upstream NF-KB regulator, IRAK-l, as shown for Mfal in (Figure 
16A). However, FimA stimulation not only degrades IRAK-l, without leading to 
induction of pro-inflammatory cytokine production (Figure 12) but IRAK-l levels remain 
minimal 24 hours after FimA stimulation and, therefore, unavailable for signaling on 
secondary TLR2 stimulation, as is shown for Mfal in (Figure 16b). Essentially identical 
results were found for IRAK-M (data not shown). 
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Figure 15: FimA induced tolerance reduces IK-Ba degradation. (A) Human PBMCs 
were pre-treated with I J.lg/ml rFimA for 24 hrs before stimulation with 1 J.lg/ml of 
rMfal for various timepoints. Immunoblots (25 J.lg protein per well) were probed for 
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Figure 16: FimA induced tolerance is lRAK-l-mediated. (A) Human PBMCs were 
pre-treated or not with 1 ~g/ml rFimA for 24 hrs before stimulation with 1 ~g/ml of 
rMfal for various timepoints . Immunoblots (30 ~g protein per well) were probed for 




Smokers are more susceptible to periodontitis and exhibit more severe disease, yet 
the normally overt inflammatory response to plaque bacteria is suppressed (274). We 
have previously shown that human monocytes challenged with tobacco smoke-exposed 
P. gingivalis respond with reduced levels of pro-inflammatory cytokines (274) and now 
show that tobacco smoke-exposed P. gingivalis promote increased IL-I0 production. 
However, the specific mechanisms of tobacco-induced innate immune suppression 
remain unknown. Initial microarray data suggested that cigarette smoke extract 
suppressed the production of P. gingivalis capsular polysaccharides while promoting the 
expression of fimbrial proteins (155, 158). As both capsular polysaccharides and fimbria I 
proteins of this key periodontal pathogen have been reported to influence cytokine 
production and because these specific bacterial structures will be the first to engage the 
host response, we hypothesized that such smoke-induced changes to P. gingivalis surface 
may contribute to the lower pro-inflammatory potential of smoke-exposed bacteria. 
We have herein established that tobacco smoke increases expression of FimA, the 
major fimbrial protein, reduces P. gingivalis capsular layer, and promotes the growth of 
P. gingivalis biofilms of increased biomass. FimA has been shown to playa critical role 
in P. gingivalis colonization of the periodontium through strong interactions with several 
host proteins, including collagen, laminin and fibronectin (284), and by promoting 
adherence to other plaque bacteria, such as Streptococcus spp. (285, 286), and the oral 
epithelia (279). Furthermore, it is long established that biofilms represent 
immunoprotective structures. FimA is an important player in P. gingivalis biofilm 
formation (287). Indeed, FimA deficient strains show reduced biofilm formation (275), 
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while non-encapsulated mutants of P. gingiva lis W83 exhibit enhanced biofilm formation 
(138, 139, 264). These results are clearly in keeping with, and provide mechanisms to 
support, established clinical observations that show that, compared to non-smokers, 
smokers are more likely to be infected with P. gingivalis (140, 141), to harbor higher 
numbers of P. gingivalis (141), and for such P. gingiva lis infections to be more persistent 
(288). 
It has been previously shown that P. gingivalis FimA interacts with TLR2 (175, 
277, 278, 289). However, the capacity of FimA to subsequently elicit an inflammatory 
response is controversial. Some research groups have shown that FimA induces the 
production of pro-inflammatory cytokines from mononuclear innate cells (158, 175) and 
have hypothesized that this contributes to the development of pathological inflammation 
(277, 289, 290). However, other studies suggest that the pro-inflammatory response to 
FimA in mononuclear innate cells may be significantly lower than that expected from 
comparable doses of classic TLR agonists (168) and is unlikely to playa major role in P. 
gingivalis-induced inflammation (244). Moreover, FimA has even been suggested to be 
anti-inflammatory (280). We now show that the CSE upregulated P. gingivalis fimbrial 
proteins, rFimA and rMfal, each signal though TLR2/1, and particularly, TLR 2/6; both 
strongly activate NF-KB transcription; but that rFimA induces a minimal pro-
inflammatory cytokine (TNF-a, IL-6) response in multiple innate cell types (human 
PBMCs, neutrophils and gingival epithelial cells) compared to rMfal and to classic 
TLR2 agonists; and also induces significant quantities of the potent anti-inflammatory 
cytokine, IL-I0. These results mimic the cytokine profiles that we have previously shown 
in innate cells stimulated with intact, CSE-exposed P. gingivalis (88, 203, 291). 
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Furthermore, these observations are in keeping with mUltiple in vivo studies in smokers 
that have shown that, despite increased susceptibility to plaque-induced periodontitis, the 
inflammatory response is suppressed in smokers compared to non-smokers (233, 234, 
236, 237). This inflammatory suppression is reflected in lower concentrations of pro-
inflammatory mediators (lL-1 ~, IL-6 and, perhaps, TNF-a) in the gingival crevicular 
fluid and periodontal tissues of smokers, compared to non-smokers (292, 293). Inefficient 
TLR stimulation and the promotion of a less vigorous inflammatory response is an 
established means of immune evasion for several pathogens, including Bordetella, 
Shigella and pathogenic Escherichia (294-297) . 
While eSE-induces functional, surface-exposed FimA expression, we further 
demonstrate that FimA induces a state of hyporesponsiveness, or tolerance, to secondary 
stimulation with Mfal, and other TLR2 specific agonists, in PBMC's - as demonstrated 
by an ablation of TNF-a and IL-6. This FimA-induced hyporesponsiveness was not 
associated with an alteration to TLR2 expression on the surface of innate cells. Rather, 
we show that FimA-induced, TLR2-specific tolerance is mediated by a suppression of 
l1d3a degradation, which is expected to be concomitant with reduced NF-KB 
translocation. 
TLR2 activation leads to the rapid recruitment of MyD88 to TLR2 and the 
subsequent recruitment of IRAK-l and IRAK-4 (298, 299). IRAK-4 phosphorylates 
IRAK-I that is in association with TLR2, allowing IRAK-l to interact with TRAF6 
(295), leading to IKBa degradation, NF-KB nuclear translocation and the induction of 
mUltiple pro-inflammatory cytokine genes (300). We show, however, that stimulation 
with FimA, leads to rapid IRAK-I degradation and the long-term unavailability of this 
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positive regulator of the TLR-2/MyD88 pathway, helping to explain FimA-induced 
tolerance. lRAK-M is a negative regulator ofNF-KB translocation that acts by preventing 
the dissociation oflRAK-1 and lRAK4 from MyD88 (301). While FimA stimulation also 
leads to the rapid degradation and chronic suppression of IRAK-M, this would appear 
inconsequential with respect to NF-KB activation because of the unavailability of 
lRAK-l. 
This FimA-induced, lRAK-1- and IKBa-involved suppressIOn of TLR2 pro-
inflammatory cytokine signaling provides one mechanism by which tobacco smoke 
dysregulates the inflammatory response and suppresses cytokine production in smokers, 
as discussed above. This mechanism of suppression may be similar to what has been 
previously reported for Pam3CSK4 (301). Monocytes stimulated with Pam3CSK4 have 
been shown to be refractory to secondary stimulation with the same agonist (280). This 
occurs due to reduced lRAK-1 protein in these cells, just as we show in FimA-tolerized 
PBMCs. 
It is important to note that there are limitations inherent in using recombinant 
proteins, particularly as they may behave entirely different outside the context of the 
whole bacterium and because of potential vector-specific alterations in the processing of 
the recombinant protein. The advantages, however, are that recombinant technology is 
long established and allows simple purifIcation of a large amount of protein that can be 
readily characterized, that is free of accessory molecules (such as associated fimbrial 
proteins FimB through E) and that allows for effective and reproducible elucidation of 
signaling pathways. Moreover FimA and Mfa1 are simultaneously expressed (150, 287), 
raising the possibility that Mfa1 may nullify the anti-inflammatory effectiveness of 
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FimA. However, FimA-comprised fimbriae are much longer appendages than the minor 
Mfa! fimbriae (150, 287) and are, thus, likely to interact with host cells prior to Mfal. 
Furthermore, it is been suggested that FimA appendages may be shed from the P. 
gingivalis surface (302) further increasing the likelihood of early FimA host interaction. 
Importantly, intact eSE-exposed P. gingiva lis that, presumably, express both Mfal and 
FimA, exhibit similar anti-inflammatory properties to recombinant FimA. While tobacco 
smoke produces multiple phenotypic and genotypic changes in P. gingivalis (280) and, 
thus, other yet to be identified mechanisms way well contribute to the overall reduced 
inflammatory response, the anti-inflammatory effects of recombinant FimA are potent 
and are likely to be a major factor in eSE-induced inflammatory suppression. 
In summary, eSE-exposure results in the upregulation of FimA. FimA suppresses 
the inflammatory response by at least two different mechanisms. One is passive, i.e. 
FimA itself engages TLR2 but has minimal inflammatory potential. The second is active, 
i.e., FimA induces TLR2 hyporesponsiveness by a mechanism involving IRAK-l 
degradation and the stabilization of IKBu. 
eSE mediated stress induces alterations in key virulence factors of P. gingivalis. 
While down-regulated capsular polysaccharides increased biofilm formation, upregulated 
fimbriae promoted TLR2 hyposensitivity in an IKBu-, IRAK-l- dependent manner. Both 
mechanisms, contribute towards altering host-pathogen interactions and reducing host-
induced inflammatory response consistent with both our prior observations that eSE-
exposed whole P. gingivalis cells have reduced inflammatory potential compared to 
control bacteria (274). These observations are also consistent with the clinical profiles of 
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smokers of severe periodontal disease who lack overt signs of clinical inflammation (88, 
203). 
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CHAPTER FIVE: SUMMARY & FUTURE DIRECTIONS 
Tobacco smoking is a major risk factor for mUltiple and varied types of diseases, 
including persistent infections, cancers, autoimmune disorders, and chronic inflammatory 
diseases - such as chronic periodontitis. The toxicity and / or carcinogenic nature of 
various chemicals found in cigarette smoke is compounded by their composite 
debilitating effects on host innate and adaptive immune responses. 
Tobacco smoke is the single most important environmental risk factor associated 
with periodontal diseases with more than 50% of cases of periodontitis found in current 
or former smokers. Compared to non-smokers, smokers show increased severity and 
incidence of periodontal disease and are highly susceptible to persistent periodontal 
infections by the Gram negative bacterial pathogen, P. gingivalis. Seemingly contrary to 
increased severity, smokers exhibit reduced signs of clinical inflammation (bleeding on 
probing, redness and edema). This thesis explains the underlying mechanisms that might 
playa role in this apparent contradiction. 
While several studies delineate the role of tobacco smoke in the skewing of 
immune response to infection very little is known about how it affects the virulence of 
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potential periodontal pathogens such as P. gingiva lis and its subsequent interaction with 
host. Components of tobacco smoke are available systemically and compromise host 
immune response. However they are readily available in the oral cavity for interaction 
with both host tissue and resident pathogenic bacteria. In this dissertation, we show that 
tobacco smoke presents an environmental stress to P. gingivalis and it adapts to this 
stress by suppressing its inflammatory profile and altering the expression of several genes 
and outer membrane proteins. Tobacco induced changes to P. gingivalis gene expression, 
phenotype and host pathogen interactions were determined to help better understand why 
exacerbated disease is accompanied by a reduced inflammatory response in smokers. 
Gross, tobacco-induced alterations caused to the P. gingivalis genome, 
transcriptional profile and phenotype were identified. We have found that P. gingivalis 
cells exposed to cigarette smoke extract (CSE) induce a reduced inflammatory profile 
(reduced levels of pro inflammatory cytokines like TNF -u, IL-6, IL-12p40) in monocytes 
and peripheral blood mononuclear cells than unexposed bacteria. This inflammatory 
suppression was consistent with identified cigarette smoke-induced transcriptional and 
post-transcriptional alterations. Microarray analysis of CSE exposed P. gingivalis 
revealed altered expression of several genes including detoxification and oxidative stress-
related genes; DNA repair genes; and multiple genes related to P. gingivalis virulence, 
including genes in the major fimbrial and capsular operons. Exposure to CSE also altered 
the expression of outer membrane proteins, most notably by inducing the virulence 
factors RagA and RagB, and a putative lipoprotein cotranscribed with the minor fimbrial 
antigen. 
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CSE exposure also resulted in phenotypic alterations such as increased fimbrial 
expression and downregulated capsular layer. Upregulated fimbriae play an important 
role in increasing persistence by forming significantly more robust biofilms. We further 
show that, while FimA is recognized by TLR2/6, the major fimbrial antigen has minimal 
inflammatory activity in several cell types. Furthermore, FimA stimulation chronically 
abrogates the pro-inflammatory response to subsequent TLR2 stimulation by other TLR-
2-specific agonists (Pam3CSK4, FSL, and Mfa1) in an IKBa- and lRAK-1-dependent 
manner. These changes may explain, in part, the altered virulence and host-pathogen 
interactions that have been documented in vivo in smokers with periodontal disease. 
Our studies demonstrate that the recombinant Mfa1 (rMfa1) is highly 
pro inflammatory. However recent work by Chris Cutler's group (172, 177) demonstrates 
that native Mfa1, isolated from P. gingivalis 381 is a glycosylated protein and is 
important in binding to DC-SIGN receptors on Monocyte derived Dendritic cells 
(MoDC). When these cells are stimulated with either wild-type Pg381 or isogenic major 
(DPG-3)-, minor (MFI)-, or double fimbriae (MFB)-deficient mutant P. gingivalis strains, 
MFI was the most potent inducer of pro inflammatory cytokines (IL-1~, IL-8, IL-6, and 
TNF-a) while DPG-3 induced significantly lower levels of TNF-nI and IL-1~ indicating a 
role of Mfa 1 in lowering pro inflammatory cytokine induction from these cells. It would 
be important to determine whether glycosylation is important in reducing the 
inflammatory potential Mfa1 and to determine whether the glycosylation patterns found 
in rMfa1 which was expressed in E. coli are different than those expressed by P. 
gingivalis strains. Alternatively, CSE exposure might result in addition of different 
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types/amounts of sugars on Mfal resulting in shifts in glycosylation patterns P. gingivalis 
proteins in a manner that promotes reduced inflammatory potential of the pathogen. 
Glycosylation of several proteins in P. gingivalis is carried out by the vim family 
of genes and inactivation of genes in the vim operon such as vimA or vimE results in 
inactivation of gingipain activity due to ineffective glycosylation of these key virulence-
associated proteases (303). Particularly, inactivation of the vimA gene, which codes for a 
39kD putative acyl-CoA N-acyltransferase, resulted in a loss of Arg-gingipain activity, 
downregulation of capsule and detection of FimA protein in the vimA defective mutant 
strain (FLL92). This is an interesting finding as the wildtype W83 strain has been 
previously shown to lack functional fimbriae and is often cited as a non-fimbriated strain 
(304). The authors also suggested that the presence of capsule might actually interfere 
with the production of fimbriae in P. gingivalis. Thus the lack of a capsular layer might 
allow for fimbrial presentation on the surface and allow for subsequent fimbriae 
dependent interactions such as biofilm formation, adherence, invasion etc. In the context 
of our studies we find that CSE exposure downregulates capsular polysaccharides while 
simultaneously promoting major fimbrial expression which is consistent with the vimA 
defective mutant strain (FLL92) phenotype. Thus it is likely that CSE alters the 
expression or activity of vimA gene product. 
Gingipains have been shown to play an important role in the processing of 
fimbrillin, the monomeric unit of the major fimbriae that is essential for the formation of 
functional fimbriae on P. gingiva lis surface (305). Gingipain activity is central to P. 
gingivalis virulence and they are essentially involved in several degradative processes 
(host tissue associated proteins as well as immune response proteins such as complement 
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components and specific cytokines). Although gingipain expression was not altered in 
microarray data it is possible that the components found is CSE might alter their 
enzymatic activity. Toxic chemicals found in cigarette smoke have an inhibitory effect 
on the enzyme activity of several host enzymes like alkaline phosphatase, gluoce-6-
phosphatase, 5'-nucleotidase, and cholinesterase in mouse liver and small intestine (306). 
While alpha, beta-unsaturated aldehydes (acrolein, crotonaldehyde) and saturated 
aldehydes (acetaldehyde) significantly inhibited salivary amylase activity due to the 
interaction between aldehydes and -SH groups of these enzymes (307). Thus it is likely 
that noxious chemicals found in cigarette smoke might alter the enzymatic activity of 
gingipains which are extracellular secreted proteases and are likely to interface with 
cigarette smoke associated toxins. 
P. gingivalis major fimbriae have been shown to be essential for inducing such 
Nf-KB downregulation and reducing the inflammatory response from macrophages that is 
associated with pathogen clearance by inducing TLR2-CXCR4 crosstalk (157). Induction 
of TLR2-CXCR4-C5aR crosstalk promotes cAMP production and subsequent cAMP 
dependent activation of protein kinase A (PKA) that is associated with downregulation of 
NF-KB activity (308, 309). In this thesis we show that rFimA has modest inflammatory 
activity but induces significantly higher amounts of IL-I0 compared to Mfal. The 
downstream signaling mechanisms behind such induction remain to be determined. One 
possible mechanism causing FimA dependent IL-I0 activation could be cAMP/cAMP-
dependent PKA activation that has been previously shown to induce IL-I0 production in 
monocytes via phosphorylation of cAMP response element binding protein (CREB) (310, 
311). Thus competition between NF-KB and CREB for binding to the coactivator CREB-
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binding protein (CBP) is important in regulating transcription of proinflammatory 
cytokines (TNFa, IL-6, IL-8, IL-IP) or the anti-inflammatory cytokine IL-I0. Whole P. 
gingivalis cells passaged in CSE also induced significantly lower levels of 
pro inflammatory cytokines (IL-6, TNF-a) and higher levels of IL-lO than control non-
exposed cells. Thus it is possible that FimA upregulation contributes towards IL-I0 
production by CSE-exposed P. gingivalis in a cAMP-PKA-CREB dependent manner and 
downregulation of N f-K13 associated transcription of pro inflammatory genes. 
There are several other negative-feedback mechanisms and signaling molecules 
that regulate TLR associated signal transduction to avert chronic TLR activation which 
might cause harmful immunological responses. In our studies we looked at one such 
regulator lRAK-M that prevents TRAF6 induced activation of IRAKI by preventing its 
dissociation from lRAKI-IRAK4 complex (300) . FimA stimulation also leads to the 
rapid degradation and chronic suppression of IRAK-M. However this would appear 
inconsequential with respect to NF-K13 activation because of the unavailability of IRAK-
1. It is possible that FimA in addition to IRAKI and IRAK-M degradation might induce 
TLR2 hyporesponsivensess through other negative regulators like Suppressor of cytokine 
signalling-l (SOCS-l) that has been shown to regulate TLR2 and 4 by targeting Mal, the 
adaptor protein important for Myd88 signaling, for polyubiquitination and subsequent 
proteosomal degradation (312). 
Besides inducing inflammatory suppression, P. gingivalis fimbriae are important 
in persistence. Persistence, in the context of the oral cavity, would not only involve host 
inflammatory suppression but also successful interaction with other colonizers of oral 
plaque by effective recruitment into oral biofilms. We have shown that the phenotypic 
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alterations caused by CSE promote P. gingivalis existence in a biofilm. Specifically CSE 
induced loss of capsular layer and upregulated fimbriae. While presence of a capsular 
layer is inversely proportional to biofilm formation (275) fimbriae are important in 
biofilm formation and FimA deficient strains cannot form effective biofilms (287). In 
mature dental plaque P. gingivalis clearly interacts with mUltiple middle and late 
colonizers, such as Actinomyces viscosus (313), Treponema denticola (314, 315) and 
Tannerella forsynthus (316). However, adhesive interactions with primary colonizers, 
such as Streptococcus gordonii, are critical for P. gingivalis colonization of the 
supragingival niche (284, 317). The early colonizers, like S. gordonii, initiate biofilm 
formation by binding to the tooth pellicle and providing an attachment surface for 
bacterial secession through multimodal receptor-ligand mediated coadhesive interactions. 
For example, the long fimbriae (FimA) of P. gingivalis bind to S. gordonii 
Glyceraldehyde-3 phosphate deydrogenase (GAPDH) (284, 318) while the shorter 
fimbriae (Mfal) bind to streptococcal SspB protein (169). An 80 amino acid sequence on 
the S. gordonii surface protein, SspB, is critical for Mfal adhesion, with a synthetic 
peptide of this SspB region, named BAR, a potent inhibitor of Mfal-dependent P. 
gingivalis-S. gordonii biofilms formation (319). As CSE upregulates fimA gene activity, 
it would be of interest to determine CSE exposure augments P. gingivalis - S. gordonii 
biofilms formation via a FimA-dependent mechanism. 
Presence of a persistent P. gingivalis infection leads to gingival ulceration and 
local vascular changes that promote transient, low level bacteremias (106) that help 
spread P. gingivalis and other periodontal bacteria from the oral cavity making 
periodontitis an important risk factor for heart disease. Viable P. gingiva lis cells, as well 
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as P. gingivalis DNA, have been found in atheromatous plaques (320, 321) while P. 
gingivalis can invade endothelial cells as well as smooth muscle cells and spread from 
infected cells to uninfected cells (322). Tobacco smoke-mediated changes to P. 
gingivalis are important contributing factors to the increased persistence of this pathogen 
in smokers and, subsequently, an increased risk for vascular inflammation and 
atherosclerotic progression. 
These studies provide some of the first information to explain, mechanistically, 
how tobacco smoke changes the P. gingiva/is phenotype in a manner likely to promote P. 
gingivalis colonization and infection while simultaneously reducing the host response to 
this major mucosal pathogen. The mechanisms responsible for periodontal disease 
induction and progression may actually be different in smokers compared to non-
smokers, demonstrating a need for differential treatment regimens. 
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